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CHAPTER 1 
INTRODUCTION 
Apart from identification of the causative microorganism, serological blood 
testing is still the principal aid in the diagnosis of venereal syphilis. In 
latent syphilis it is in fact the only diagnostic aid. In the diagnosis of late 
symptomatic syphilis, additional organ-specific diagnostic procedures are 
indispensable. 
Interpretation of the results of serological syphilis tests often poses prob-
lems in actual practice. Apart from possibly inadequate knowledge of the 
natural history of the disease and the course of serological syphilis tests, 
this may be due to the fact that a fairly large number of different tests are 
in use in The Netherlands. Often, moreover, a single laboratory result is 
expected to give a definite diagnosis. 
There are numerous views and recommendations with regard to the treat-
ment of syphilis. Recent studies on an international level have shown that 
no definite conclusions can as yet be formulated in this respect (Luger, 
1968; ldsoe et al., 1972; Thompson et al., 1976). 
In the dermato-venereological department of the Rotterdam University Hos-
pital, well-documented case records of syphilis patients were available. 
Several different serological tests had been performed in these cases, 
both before and after treatment. It was therefore possible- within the con-
text of the research project !Jnteraction between Man and Treponema pall i-
dum• now in progress in the department - to carry out a retrospective 
study of the results and interpretation of serological tests both before and 
after treatment in groups of syphilis patients. Specifically, it was possi-
ble to compare a relatively large number of different tests within a given 
group of patients. 
Chapter 2 and 3 present a survey of clinical symptoms, the treatment of 
syphilis, and general aspects of serological tests in current use. 
Chapter 4 through 8 present and discuss personal observations. 
CHAPTER 2 
SYPHILIS. • CLINICAL AND THERAPEUTIC ASPECTS 
2. 1. Introduction 
There are several theories on the origin and dissemination of syphilis. 
One of these theories holds that Columbus and his crew brought syphilis 
back from the New World to Spain and then to Naples, whence it spread 
over Western Europe. Others maintain that syphilis was already present 
in Europe at that time. The disease was originally known as lues venera. 
The term syphilis, now most widely used internationally, was introduced 
in the 16th century by Ricord and derives from a 16th-century poem about 
the shepherd Syphilus ('friend of swine'}, who was suffering from evil 
sores. 
2. 2. Pathogenesis 
2. 2. 1. Causative microorganism 
Syphilis is the principal representative of the diseases caused by micro-
organisms of the species Treponemata. Syphilis (synonym lues) is caused 
by Treponema pallidum (T. pallidum). Other treponematoses are framboesia 
(yaws), caused by T. pertenue, and pinta, caused by T. carateum. These 
treponemata are not distinguishable either morphologically or serological-
ly but it is possible to demonstrate the development of distinctly different 
characteristic changes in animal experiments. Other treponemata are 
saprophytes: T. macrodentium and T. microdentium on the oral, and 
Borrelia refringens on the genital mucosa. The presence of these sapro-
phytes can impede laboratory investigation of ulcers. The causative 
microorganism of syphilis, T.pallidum, is a very delicate, spiral- or 
corkscrew-shaped organism which varies in length from 8 to 19 p. In a 
native physiological saline preparation, both the shape and the movements 
of the microorganism can be visualized by dark-field or phase-contrast 
microscopy. Three characteristic movements are distinguishable: 
• 
The text of this chapter is a rendering, with a few additions and correc-
tions, of the Dutch text of the chapter on 'Syphilis' which the author 
wrote for the textbook on dermatological and venereal diseases, Huid- en 
Geslachtsziekten, Bohn; Scheltema & Holkema, Utrecht 1980. The 
publisher has kindly permitted the author to use this text. 
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rotation on the longitudinal axis, a forward movement in the direction of 
the longitudinal axis, and flexible lateral movements. 
In tissue sections, treponemata can be demonstrated with the aid of a 
silver stain (Whartin and Starry, 1921). Direct and indirect immunofluor-
escence techniques can also be used to demonstrate treponemata in tissues 
and body fluids (cerebrospinal fluid, vitreous fluid, endolymph) (Wilkinson 
and Cowell, 1971). 
In its active phase, the organism divides itself transversely about once 
every 30 hours. It is assumed that, after a prolonged presence of the 
organism in the host, this interval between divisions can be markedly 
increased: up to several days {Rosahn and Rowe, 1950). The number of 
treponemata presumably increases graduallY during the infection, well 
into the second stage, whereupon it decreases. Outside the body, T.palli-
dum can survive only a few hours. Attempts to cultivate T. pallidum on an 
artificial medium have so far failed, but cultivation by inoculation of test 
animals (rabbit, monkey) is possible. Under very special conditions (anaer-
obic environment), T. pallidum can live in artificial nutrient media for a 
few days without dividing. 
2. 2. 2. Mode of infection and infectiosity 
Infection generally takes place via intimate physical contact, of which 
sexual intercourse is the example par excellence. T.pallidum must be 
present on the skin or mucosa of the contact involved. Another prerequi-
site for infection is that the treponemata can pass the epidermal barrier. 
This poses no difficulty at the sites of epithelial defects and at sites 
normally devoid of epidermis: the mucosa. It is generally believed that the 
disease is no longer a localized condition a few hours after infection. 
Physicians and medical personnel can be accidentally infected via a skin 
lesion after contact with blood from a patient with infectious syphilis. 
Syphilis can also be transmitted by blood transfusions using fresh blood 
from persons suffering from early syphilis. 
Although it is theoretically impossible to define limits of infectiosity, it 
is assumed that only untreated early syphilis (i.e. untreated syphilis 
within 2 years of the infection) must in practice be regarded as infectious. 
An exception to this rule is untreated syphilis in a pregnant woman: when 
no adeQ.Jate treatment has been given, infection of the foetus in utero is 
possible even more than 2 years after the infection {Stokes et al., 1941). 
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2. 3. Histopathology 
The fundamental histological changes in syphilis are localized in and 
around the blood vessels; in particular there is a predominant perivascu-
lar infiltrate of lymphocytes and numerous plasma cells, and endarteritis 
and endophlebitis. In tertiary syphilis (gummatous forms) one finds in addi-
tion a tuberculoid infiltrate with caseation, which may cause a close 
resemblance to tuberculosis. In such cases the vascular lesions and the 
plasmocellular infiltrate can be helpful in differential diagnosis. 
2.4. Specific defence 
Humoral: 
Even in the sero-negative stage of syphilis, an increased serum immuno-
globulin concentration can be observed which attains its maximum during 
the secondary stage. The principal contribution to this increase is made 
by immunoglobulins of the lgG and lgM classes. Penicillin treatment 
during 6 weeks causes a return of immunoglobulin levels to virtually nor-
mal values {Menke, 1975). An increased lgE level, too, has been demon-
strated in early syphilis {Green et al., 1976; Bos et al., 1980a). 
The presence of antibodies against T. pallidum can be demonstrated with 
the aid of several serological tests. There are indications that several 
nonspecific antibodies are synthesized during an infection with T.pallidum, 
as demonstrated by an increased presence of rheumatoid factor and anti-
bodies against the patient's own erythrocytes {Doniach, 1976). Moreover, 
fluorescence has been described in various tissue substrates, including 
epidermal tissue, with sera from patients with early syphilis {DeJong et 
al., 1978). 
Cellular: 
When a purified extract of pathogenic treponemata is intracutaneously in-
jected, a skin reaction may develop which, in view of the chronological 
course and the histological characteristics, can be plausibly regarded as 
a delayed-type hypersensitivity reaction. Patients with early syphilis 
nearly always show a negative reaction, whereas the reaction in those 
with late syphilis is often positive (Csonka, 1950; Huriez et al., 1961). 
Patients with late symptomatic syphilis likewise frequently show a posi-
tive reaction, with the exception of those with dementia paralytica, whose 
skin reaction is negative. In the latter patients the serological tests show 
high titres and vast numbers of treponemata are found in the body 
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{Stokes et al., 1941). It has also been found that neonates with congenital 
syphilis- unlike healthy neonates- could not be sensitized by means of 
the obligate sensitizing agent dinitrochlorobenzene (Parent and Smythe, 
1973). 
Histological examination of lymphoid organs has revealed lymphocyte 
depletion in the paracortical areas of lymph nodes in patients with early 
syphilis and in the periarteriolar sheaths in the spleen of children who 
died from congenital syphilis. These areas in lymph nodes and spleen are 
thymus-dependent areas in which mainly T-!ymphocytes are normally 
localized (Levene et at., 1971; Turner and Wright, 1973). Moreover, 
there are indications of a decrease in the number of circulating T -lympho-
cytes in primary syphilis (Bos et al., 1980b). There is as yet no agree-
ment about the question whether the in-vitro phytohaemagglutinin (PHA) 
response of lymphocytes from patients with primary and secondary syphilis 
is or is not diminished as compared with that in normal controls. EquallY 
controversial is the question whether plasma from these patients is able 
to suppress the PHA response of lymphocytes from healthy donors. It 
seems to be an established fact that lymphocytes from patients with early 
syphilis are less readily stimulated than those from normal controls when 
submitted to the influence of a protein preparation isolated from 
T. refringens, which is related toT. pallidum. From this fact it has been 
concluded that suppression of cellular immunity is involved, which remains 
limited to the treponema! antigens (From et al., 1976). 
Considering the specific immunological defence, we are confronted with 
relatively early stimulation of the antibody-producing apparatus, leading 
to synthesis not only of antibodies against treponema! antigens but also of 
antibodies of 1deviant' specificity. Progression of the disease takes place 
in spite of the production of these antibodies. Cellular immunity, on the 
other hand, develops only late in the course of the infection, and several 
lines of research indicate the possibility of a disorder at the T-lymphocyte 
level during early syphilis. 
2. 5. Subdivision of venereal syphilis 
The traditional division·of syphilis into three stages- primary, secondary 
and tertiary syphilis- is in fact arbitrary, and the stages often overlap. 
Yet this subdivision is still widely used and found satisfactory in day-to-
day practice. Another subdivision is that into early infectious syphilis 
(primary, secondary and early latent syphilis) and late syphilis (late 
I a tent and symptomatic syphi I is). 
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2. 6. Early infectious syphilis 
2. 6.1. Primary syphilis 
2. 6. 1. 1. Incubation period 
The incubation period averages 17-28 days (extremes: 9 and 90 days). 
2.6.1.2. Localization 
The lesion is usually localized in the anogenital region or areas near the 
external genitals (pubic region, scrotum). Extragenital localizations-
mouth, lips, fingers- are rare (De Koning eta!., 1977). In some cases 
the patient is unaware of the ulcers due to their unusual localization, e. g. 
rectum, vaginal wall and cervix uteri. In these cases the inguinal lymph 
nodes are often not swollen either. This explains the fact that women and 
homosexuals who practice rectal intercourse, often present in a later stage 
of syphilis (usually secondary). 
2. 6. 1. 3. Characteristics 
A generally painless papule with an eroded surface or an ulcer develops 
on the mucosa or at the site of a skin defect. The ulcer may be indurated, 
in which case it is called ulcus durum or hard chancre. Not infrequently, 
however, there are atypical lesions such as multiple superficial ulcer-
ations of herpetiform appearance, erosive balanitis and, sometimes, 
markedly inflammatory oedema with paraphimosis. Reports in recent years 
have mentioned an increase in the incidence of atypical primary lesions, 
up to 40% of the total number of patients with primary syphilis (Notowicz 
et al., 1973). An ulcer without regional lymph node swelling is called 
primary lesion, but when it is associated with painless, palpably hard 
regional lymph node swelling, it is known as primary complex. Left un-
treated, the pr·imary lesion heals within 3-8 weeks, sometimes leaving a 
slightly atrophic cicatrix. 
2. 6. 1. 4. Differential diagnosis 
Possibilities to be considered in differential diagnosis include herpes 
genital is, common forms of balanitis, scabies papules irritated by scratch-
ing, chancroid, lymphogranuloma venereum, donovanosis and common 
traumatic lesions. Carcinoma of the penis also is often associated with 
ulceration. In patients with a genital lesion, syphilis can be eliminated 
only by careful history taking (including family history if necessary), 
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clinical examination, repeated dark-field and serological studies and 
serological follow-ups over a period of 3 months. 
2. 6. 2. Secondary syphilis 
2. 6. 2. 1. Incubation period 
When primary syphilis is not identified and treated as such, the symptoms 
will nevertheless subside and finally disappear, but subsequently the 
symptoms of secondary syphilis can develop- on average 6 weeks after 
development of the ulcer (extremes: 1 and 6 months). A transitional form 
in which the symptoms of primary syphilis are still present, can also 
develop. 
2. 6. 2. 2. Characteristics 
The most general symptoms of secondary syphilis are syphilitic exanthem, 
generalized lymph node swelling and the presence of condylomata lata and 
mucous patches. Patients often develop general symptoms such as malaise, 
fever, headache, sore throat, hoarseness, arthralgia and osteodynia. 
The skin lesions in secondary syphilis can assume a multitude of forms. 
As a rule the first lesions are the so-called macular syphilids: faintly 
rose-coloured spots with a diameter of about 1 em which can appear any-
where on the body but show a predilection for the handpalms and footsoles. 
After some time these spots, not readily identifiable and therefore some-
times overlooked by the patient, turn into papules with the same gener-
alized distribution; later, desquamation on the papules may give rise to 
papulosquamous or (especially on handpalms and footsoles) psoriatiform 
efflorescences. Especially on the skin of the face and scalp, pustules 
may form which sometimes impress as acneiform, while in other cases 
more sharply elevated papule-pustules are seen in foil icular arrangement. 
Patchy loss of hair is another very typical feature: ill-defined patches 
show unmistakably Jess hairgrowth, and differentiation from alopecia 
areata is therefore not difficult. This syphilitic alopecia is known in 
Anglo-American literature as 1moth-eaten alopecia'. Condylomata lata 
are characteristic efflorescences at the transition between skin and 
mucosa. They are flat, hypertrophic, flesh-coloured papules with a broad 
base and a greyish-white or eroded surface. They can also occur at other 
warm, moist sites, e. g. scrotum, axillae, umbilicus and between the toes. 
The most frequent localizations are the perianal area, genitals and corners 
of the mouth. Mucous patches can also occur: slightly elevated oval plaques 
7 
with a greyish -white surface on the genitals, anal mucosa and in the oral 
cavity. Owing to the very superficial presence of treponemata, condylo-
mata and mucous patches are the most infectious lesions in secondary 
syphilis. Other, more general symptoms in secondary syphilis can be: 
acute uveitis, hepatomegaly and splenomegaly as an expression of hepatitis, 
sometimes associated with jaundice and headache, as an expression of 
meningeal irritation. VVhen left untreated, the efflorescences can disap-
pear after 1-3 months. Some 25% of these patients subsequently show re-
lapse or exacerbation of the skin lesions. 
2. 6. 2. 3. Diagnosis 
As in primary syphilis, dark-field microscopy is necessary also when 
secondary syphilis is suspected. It can be done without difficulty by ob-
taining specimens from the eroded surface of condylomata lata or mucous 
patches, or after scarification of a papule on the intact skin. In addition, 
serological tests (both treponema! and non-treponema!) are positive in 
1 OOo/o of cases, with high tit res in the non-treponema! tests. Histological 
examination can also contribute to diagnosis, particularly in cases with 
atypical symptoms (Notowicz et at., 1975). 
2. 6. 2. 4. Differential diagnosis 
The already mentioned variety of dermatological symptoms in secondary 
syphilis of course implies the necessity of differentiation from a large 
number of dermatoses. To be taken into account in particular are other 
causes of generalized exanthem (e. g. toxicoderma, virus diseases) and 
erythemato-squamous conditions (e. g. pityriasis rosea, seborrhoeic 
eczema, psoriasis) and conditions characterized by the presence of 
papules (e. g. lichen ruber). 
2.7. Early and late latent syphilis 
After weeks or months, secondary syphilis can show gradual transition to 
the latent phase, characterized by definition by the absence of clinical 
symptoms. The patient harbours T.pallidum in the lymphoid tissue (Collart 
eta!., 1964), and there seems to be a state of equilibrium between para-
site and host. In the latent phase, the diagnosis is established on the basis 
of repeated unchanged positive serological tests in the absence of clinical 
symptoms and without indications of neurosyphilis and cardiovascular 
syphilis. Further investigation by the organ specialists involved is 
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required for this purpose. Latent syphilis can be divided into early and 
late latent forms, dependent on the interval since infection. A condition is 
diagnosed as early latent syphilis when anamnestic and/or epidemiological 
data suggest that the infection is of less than 2 years 1 standing and when 
treponema! serological tests are positive in the absence of clinical symp-
toms. Lymphadenopathy may be the sole manifestation. Early latent 
syphilis is a stage of early infectious syphilis. In the case of an infection 
of more than 2 years 1 standing, the condition is diagnosed as late latent 
syphilis. 
In some cases with positive serological tests without clinical symptoms 
and with no anamnestic evidence of syphilis, differentiation from yaws or 
other treponematoses is necessary, particularly when the patients come 
from regions where these diseases are stilI endemic. In The Netherlands, 
this has to be taken into account in particular in the interpretation of 
positive serological tests in patients who originate from Surinam (Menke 
et al., 1979; Niemel et al., 1979). In some instances it may be necessary 
also to differentiate between acquired latent syphilis and latent congenital 
syphilis. 
The importance of the detection and treatment of cases of latent syphilis 
lies in the fact that this can prevent development of tertiary syphilis in the 
majority of cases. 
2. 8. Late syphilis (tertiary syphilis) 
Studies by Gjestland (1955) concerning a group of untreated syphilis 
patients collected by Boeck during the period 1891-1910, show that about 
33% of the untreated patients recover spontaneously, while another 33% 
remain in the latent stage for life, and a final 33% develop signs of late 
(tertiary) syphilis. Symptoms of late syphilis can develop 3-12 years after 
infection, but often occur even much later. In this stage, dark-field micro-
scopy of specimens from the lesions is useless because only few trepone-
mata are present in this material. The non-treponema! serological tests 
are often negative, but may be strongly positive in active late symptomatic 
syphilis. Treponema! syphilis tests are nearly always positive. The 
incidence of late symptomatic syphilis has substantially decreased as a 
result of the penicillin treatment of early syphilis. 
Of the various forms of symptomatic syphilis, only gummatous syphilis, 
cardiovascular syphilis and neurosyphilis will be briefly described. 
It should always be borne in mind that, as a result of the bacteraemia in 
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the early stage of the disease, treponemata can have settled anywhere 
and in any organ system. 
2. 8. 1. Gummatous syphilis 
A gumma should be regarded as a violent, mainly cellular reaction to the 
presence of a small number of treponemata with which the organism has 
previously co-existed in peace. A solitary gumma or multiple gummata 
may be present. A gumma is histologically characterized by localized or 
diffuse chronic granulomatous inflammation. In the localized form, one 
observes a central necrotic area surrounded by granulation tissue and 
a more peripheral zone of fibrosis. The granulation tissue contains a 
perivascular infiltrate of lymphocytes, plasma cells, epitheloid cells and 
giant cells. The surrounding tissue shows endarteritis obi iterans. 
Gummata can be found in skin, subcutaneous tissue, mucosa, bones and 
visceral organs. Nodose or tuberculo-ulcerous lesions in tertiary syphilis 
of the skin are the most superficial forms. Like the gummatous forms, 
they are solitary, asymmetrical, indurated and painless; they often show 
a sharply defined arched boundary, and may be associated with central 
necrosis with a tendency to central or unilateral healing with cicatrization. 
Polycyclic lesions with irregular contours can thus develop. In some cases 
the lesions can be covered by psoriasiform squamae. These lesions (like 
those in tuberculosis of the skin, for example) can show an applesauce 
colour at diascopy. Gummata are as a rule localized at a deeper level, in 
the subcutis, and can spread both to the surface and to deeper levels. The 
absence of pain is a striking feature. As a rule there is central ulceration 
with perforation to the outside or into one of the body's cavities. In that 
case there results a typical punched-out ulcer with necrotic margins, and 
often also a polycyclic demarcation due to perforation at several sites. 
Localizations of predilection are the face, scalp, chest and calves. 
Gummata in the tongue can occur in either solitary or multiple form, some-
times with ulceration, and sometimes with diffuse infiltration producing 
the features of chronic interstitial glossitis, which ~hould be regarded as 
precarcinomatous. Destruction of the nose produces a characteristic 
feature of late congenital syphilis: the so-called saddle-back nose which 
results from collapse of the nasal septum. 
10 
2. 8. 1. 1. Differential diagnosis 
All conditions associated with granuloma formation and/or ulceration are 
to be considered: tuberculosis, leprosy, sarcoidosis, chronic pyoderma, 
iododerma and tumours. 
2. 8. 2. Cardiovascular syphi I is 
Vascular lesions are very important in the pathogenesis of organ lesions 
in syphilis. Clinical symptoms of cardiovascular syphilis usually develop 
late: 10-30 years after the infection. Some form of neurosyphilis is pre-
sent in 25% of the patients with cardiovascular syphilis. 
2.8.2.1. Clinical symptoms 
The principal symptoms in the majority of cases are symptoms of aortitis 
as a manifestation of inflammatory lesions in the aortic wall. Endarteritis 
of the vasa vasorum leads to ischaemic changes, followed by degeneration 
of the elastic tissue of the tunica media of the vascular wall, and fibrosis. 
The intima of the aortic wall is likewise damaged and shows characteristic 
cicatrization with atheroma formation and calcifications. This damage to 
the aortic wall may give rise to aneurysmal dilatations, which sometimes 
produce characteristic changes in the chest X-ray. The ascending aorta 
is most frequently affected, with lesions beginning dose to the aortic 
valves so that aortic insufficiency may develop. The coronary ostia may 
also be affected, with clinical symptoms of coronary ischaemia. True 
syphilitic myocarditis and gummata in the aortic wall or myocardium are 
rare; given a cardiac localization, they may give rise to arrhythmia. 
Aneurysms of the aortic arch, descending aorta and abdominal aorta can 
also occur, but are very rare. 
2. 8. 3. Neurosyphilis 
Invasion of the central nervous system and meninges occurs in early 
syphilis during generalization of the infection. In the majority of cases 
this causes no symptoms; headache and signs of mild meningeal irritation 
can as such be part of the symptomatology of secondary syphilis. Acute 
syphilitic meningitis is a rare development in early syphilis. 
2. 8. 3. 1. Diagnostic procedures 
Apart from a detailed history, clinical neurological examination and 
serological blood testing, cerebrospinal fluid studies are of essential 
11 
importance. Of the various laboratory procedures- e. g. cell count, total 
protein, globulin, serological tests and colloid tests- the first two in 
particular are very sensitive but give no specific criteria. 
2. 8. 3. 2. Asymptomatic neurosyphilis 
The term asymptomatic neurosyphilis applies when there are cerebro-
spinal fluid changes of a pattern consistent with neurosyphilis, but no 
clinical neurological symptoms, in a patient with latent syphilis, treated 
or untreated. This condition certainly requires treatment and, when left 
untreated, can progress to symptomatic neurosyphilis (Van Vliet, 1973). 
2. 8. 3. 3. Late signs of symptomatic syphilis of the nervous system 
The late signs of syphilis of the nervous system can be divided into two 
main forms: 
a. Meningovascular syphilis 
The blood vessels of the brain, spinal cord and meninges show prolifer-
ative endarteritis with a perivascular infiltrate of lymphocytes and plasma 
cells, followed by fibrosis and tissue necrosis due to thrombotic proces-
ses. The symptomatology usually varies widely with the different local iza-
tions of the process within the central nervous system. The principal 
early symptoms of this form of neurosyphilis are irregular, unequal pupils 
with a delayed response to light (Argyll Robertson pupils) and abnormal 
leg reflexes. Cerebral signs of meningovascular syphilis are basal 
gummatous meningitis, cerebral endarteritis and, rarely, cerebral gum-
mata. Meningomyeli"tis, syphilitic amyotrophy, spastic paraplegia, hyper-
trophic pachymeningitis and spinal endarteritis are among the spinal signs 
of this form of neurosyphilis. 
b. Parenchymal syphilis 
This form is subdivided into: 
1) Dementia paralytica: 
In dementia paralytica there is involvement of the cerebral parenchyma 
with atrophy of the cerebral cortex. The earliest symptoms are generally 
intellectual deterioration, loss of memory, reduced ability to concentrate, 
faulty judgement and changes of mood, later followed by delusions and 
dementia. Neurological changes include tremors, pupillary abnormalities, 
dysarthria, dyslexia, convulsions, incontinence and pyramidal symptoms. 
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2) Tabes dorsal is: 
Tabes dorsalis involves the spinal cord. Characteristic features are 
ataxia of the lower limbs and signs of degeneration of the dorsal columns. 
The clinical symptomatology varies widely and includes fulgurant 
(•shooting') pains in the legs, ataxia, numbness, disturbed bladder func-
tion, impotence, diminished visual acuity, severe abdominal pains and 
arthropathies. Associated neurological changes are very extensive. 
2. 9. Pregnancy and syphilis 
2. 9. 1. Introduction 
The diagnosis of syphilis in pregnant patients does not differ in principle 
from that of syphilis in non-pregnant patients. However, the distinction 
between early infectious syphilis and late latent syphilis is very important 
with a view to the timing of treatment. Serological tests for syphilis are 
routinely performed in every pregnant woman. Since false-positive non-
treponema! tests are occasionally seen during pregnancy, it is important 
to perform at least one treponema! serological test. Another important 
argument in favour of this is the fact that titres of non-treponema! anti-
bodies tend to fall with a longer duration of syphilis (and can totally 
disappear after some time). This explains that non-treponema! tests can 
be negative in a pregnant woman even though she is suffering from late 
syphilis- as demonstrated by a positive treponema! test. 
2. 9. 2. Mode of infection 
Intrauterine infection takes place via placental passage of treponemata, 
which is not possible until after the fourth month of pregnancy. It is 
therefore useful to test the pregnant woman for syphilis in the earlier 
phase of pregnancy (e. g. the second or third month). Early diagnosis 
allows early institution of treatment, i.e. before the fourth month. Since 
a pregnant woman can still be infected with syphilis after the third month, 
theoretical it is advisable to repeat syphilis tests towards the end of term. 
2. 9. 3. Therapeutic approach of the pregnant patient 
The treatment of pregnant syphilis patients primarily aims at prevention 
of congenital syphilis in the neonate to be. Women with early syphilis 
(primary, secondary, early latent) should be treated as soon as the diag-
nosis is established. In late fatent syphilis, the maximum preventive effect 
of treatment cannot be expected until the fourth-to-fifth month of pregnancy. 
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Treatment later in the course of pregnancy is intended as curative treat-
ment of a possibl·y already infected foetus. Whether treatment should be 
repeated during a subsequent pregnancy is considered by some authors to 
depend on the outcome of the Treponema Pallidum Immobilization (TPI) test. 
As long as the TPI test remains positive, T. pallidum may be present in the 
patient's body (Coli art, 1962). The presence ofT. pallidum constitutes a 
potential danger of infection of the foetus, and thus provides an argument 
in favour of repeated treatment during a subsequent pregnancy (Degas, 
1971). Other authors consider the risk of a neonate with congenital 
syphilis to be much smaller after adequate treatment during a previous 
pregnancy, and therefore advise against repeated treatment during a sub-
sequent pregnancy (Lindemayr and Partsch, 1976). 
2.9.4. Conduct at delivery and during the first months of life of an 
infant with possible congenital syphilis 
Women in whom early syphilis has been diagnosed, should be delivered in 
a clinical setting. Whether this is also necessary in the case of late latent 
syphilis, is debatable. In any case it is important to submit every neonate 
with a syphilitic mother to a detailed physical examination for evidence of 
congenital syphilis, regardless of the stage of the mother's disease and 
the nature of the treatment given. 
Serological tests are very important in diagnosing neonatal syphilis. 
Positive tests in the neonate can be based either on passive transfer of 
antibodies from mother to child, in which case the latter is not infected, 
or on active production of antibodies in the child, in which case the child 
is infected. If at the time of delivery the neonatal antibody· tit res are high-
er than those in the mother, infection of the neonate is a possibility to be 
seriously considered. A fall of the titres during the first three month 
after birth should be regarded as an argument against infection, whereas 
unchanged or rising titres provide an argument in favour of infection. In 
actual practice the diagnosis of congenital syphilis may be problematic, 
and some time may pass before the diagnosis is established. The possibil-
ity to perform the FTA-lgM test can be an asset in the diagnosis of con-
genital syphilis, because lgM antibodies specifically indicate a recent in-
fection. 
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2.9.5. Consequences of maternal syphilis for the foetus 
Syphilis during pregnancy can have the following consequences for 
the foetus: 
1) premature birth (Jess than 16 weeks of pregnancy); 
2) intrauterine death late in the course of pregnancy; 
3) birth with signs of syphilis; 
4) birth in apparent health, but development of signs of early congenital 
syphilis after a few weeks or months; 
5) late congenital syphilis (symptoms developing after the second year of 
life); 
6) no infection. 
2. 9. 6. Diagnosis of syphilis in neonates 
Three points are important in the diagnosis of syphilis in neonates: 
1) Examination of the placenta: in the case of syphilis this is too heavy 
and pale, and shows typical histological changes (endarteritis and an 
infiltrate of mostly plasma cells). 
2) Examination of the neonate (with special reference to symptoms of 
early congenital syphilis). 
3) Serological testing. 
2. 9. 7. Early congenital syphilis (infectious, 0-2 years) 
Early congenital syphilis is rare in The Netherlands. Symptoms may be 
marasmus, senile face, yellowish-brown (cafe-au-lait) complexion, 
snuffles. The skin may show macular, papular, maculopapular, bullous 
and polymorphous exanthems of symmetrical localization, especially 
around the mouth, in the anogenital region and on the handpalms and 
footsol es. Additional symptoms include onychia, paronychia, condylomata 
lata and osteopathies such as osteochondritis (epiphysitis), Parrot's 
pseudo-paralysis and periostitis. There may also be hepatomegaly asso-
ciated with syphilitic cirrhosis, splenomegaly, pneumonia, syphilitic 
meningitis, asymptomatic neurosyphilis, iritis and chorioretinitis. 
2.9.8. Late congenital syphilis (non-infectious, age over 2) 
Late congenital syphilis is likewise rare in The Netherlands, but less 
rare than early congenital syphilis. The principal symptoms are gummata, 
preferable in the nose and mouth, with subsequent malformation of the face. 
There is also periostitis, often of the tibiae and leading to deformity 
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(sabre-shaped tibiae). Interstitial keratitis, chorioretinitis, uveitis and 
optic atrophy are important ophthalmological findings. Synovitis with 
painless swelling and hydrops (so-called Clutton joints) produces charac-
teristic radiological changes. Physical and mental retardation and clini-
cally manifest neurosyphilis (juvenile tabes dorsalis and dementia para-
lytica) were in the past interpreted as evidence of 'constitutional inferior-
ity' of these patients. 
2.9.8.1. Stigmata of late congenital syphilis 
Stigmata are marks which the patient carries all his life as evidence of 
his (her) intrauterine infection with syphilis. Scars and deformities 
resulting from some of the abovementioned conditions are often permanent. 
Localized thickening due to periostitis of the fror.~al and parietal cranial 
bones results in a skull of characteristic appearance. Malformation of the 
nasal bones leads to flattening of the dorsum of the nose: the so-called 
saddle-back nose. The palate is often arched high. The mandible protrudes 
and causes a bulldog face. The teeth likewise show typical abnormalities 
{Hutchinson teeth). Other possible stigmata are: corneal cicatrization, 
perforation of the nasal septum or palate, sabre-shaped tibiae, long-
standing choroiditis, optic atrophy and sensorineural hearing loss. 
2. 1 0. Therapy 
Penicillin, which acts on the dividing treponema, is the agent of choice 
in the treatment of syphilis. The general principle is that a penicillin 
concentration of at least 0. 03 U/ml serum should be maintained during 
several times the generation period ofT. pallidum (about 33 hours). 
Whether this generation period of about 33 hours also applies toT. palli-
dum in the human organism during a longstanding syphilis infection, is not 
entirely certain. For lack of an in-vitro cultivation technique, there are no 
exact studies of the sensitivity ofT. pallidum to antibiotics. Although pen i-
cillin has been used in the treatment of syphilis for over 30 years, there 
seems to be no diminished penicillin sensitivity of the treponemata. 
T. pall idum-like structures have been repeatedly demonstrated in the eyes, 
cerebrospinal fluid, lymph nodes and bones of patients formerly treated 
for early or late syphilis (Editorial 1968). In some of these cases it was 
demonstrated by inoculation of rabbits that these structures were indeed 
virulent T. pallidum. The consequences of their persistent presence (can 
they cause a flare-up of symptoms; can they infect the foetus in utero?) 
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are not clear. The question arises whether the generally accepted mini-
mum treponemicidal penicillin concentration and the presumable generation 
period ofT. pallidum are in fact correct. 
A great many syphilis therapies have been described, which can be grossly 
divided into two categories: the relatively short Anglo-American and the 
relatively long European penicillin courses. The arguments in favour of 
the longer courses are based on the above-mentioned uncertainties about 
the generation period of T.pallidum and the apparent possibility of persis-
tence of the causing organism in spite of therapy. 
In several Dutch university hospitals, early syphilis and late latent 
syphilis without organ lesions were treated by fairly long courses of 9-
10.8 million IU procaine-penicillin in oil with 2% aluminium monostearate 
(Aimopen®, PAM} intramuscularly, divided over a period of 4-6 weeks. 
Almopen has been unavailable in The Netherlands since May 1980. The 
Rotterdam university hospital now uses aqueous procaine-penicillin G 
(Depociflin®}- 600.000 IU daily intramuscularly over a period of 2-3 
weeks. 
The guidelines of the American Ministry of Health (Center for Disease 
Control, Atlanta) indicate substantially shorter courses of treatment: 
for early syphilis, 2.4 million IU benzathine penicillin (Penidural®) 
intramuscularly or 4. 8 million lU aqueous procaine-penicillin Gover a 
period of 8 days, or procaine-penicillin in oil with 2% aluminium mono-
stearate- 2.4 million lU to begin with, followed by 2 x 1.2 million IU 
at three-days intervals. 
In late latent syphilis in which no further examination has been done, or 
in verified symptomatic syphilis, more intensive therapies are indicated 
e.g. 1.2 million IU procaine-benzylpenicillin/sodium-benzyl-penicillin 
(3:1) (Bicifline®) daily for two weeks, followed by 1.2 million IU ben-
zathine penicillin/procaine-penicillin G/potassium-penicillin G (2:1:1) 
(Penidural DF®} twice weeki y during four weeks, up to a total of 31,2 
million IU penicillin. In early and late congenital syphilis (up to 12 years} 
treatment with 20.000 U Bicilline® per kg body weight during six weeks 
is recommended. 
In a recent investigation it was shown that, in the treatment of neuro-
syphilis with 1.2 million IU benzathine penicillin thrice weekly or with 
a daily intramuscular dose of 600.000 IU procaine-penicillin G, no trepone-
micidal concentrations in the cerebrospinal fluid were attained (Dunlop et 
a/., 1979). It was however possible to obtain such concentrations by 
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intramuscular injection of 4 x 500.000 IU aqueous penicillin Gin combina-
tion with 500 mg probenecid by mouth, or by daily intramuscular injection 
of 2.4 million IU aqueous procaine-penicillin Gin combination with 4 x 500 
mg probenecid per day by mouth. Alternative courses of antimicrobial 
therapy are conducted with tetracycline hydrochloride or erythromycin, 
2 g per day by mouth in four divided doses during 30 days. 
Views on follow-up also differ widely. In any case a serological follow-up 
should take place at regular intervals. In addition a follow-up with special 
reference to possible late symptomatic syphilis should be made in col !abo-
ration with the relevant organ specialists 2 years after early syphilis. 
2.10.1. Side effects of treatment with penicillin 
Treatment of syphilis with penicillin can give rise, not only to various 
allergic reactions but also to two unusual side effects. The first of these 
is an acute non-allergic reaction after administration of aqueous procaine-
penicillin (Hoigne•s syndrome). This syndrom in its typical form is charac-
terized by severe acute sense of depersonalization, verbalized fear of 
death and hallucinations. On examination these patients are shown to have 
tachycardia, increased blood pressure and dilatation of the pupils. These 
symptoms are quickly reverted by intramuscular administration of 10 mg 
diazepam (Pepplinkhuizen et al., 1977). The second side effect is the 
Jarisch-Herxheimer reaction, either systemic with fever and leucocytosis 
or localized with exacerbation of existing skin lesions. There are several 
aetiological theories. The reaction might be due to release of endotoxins 
from destroyed treponemata, or release of leucocytic pyrogens after 
phagocytosis of membrane fragments from treponemata. Release of hista-
mine as a result of degranulation of mast cells and basophils in response 
to combination of treponema] antigens with membrane-bound antitreponemal 
lgE might also explain some features of this reaction (Bos et al., 1980a). 
This reaction generally requires no therapy, but the patient should be 
warned that it may occur. 
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CHAPTER 3 
SEROLOGICAL TESTS IN SYPHILIS. A GENERAL SURVEY 
3. 1. Introduction 
Serological tests used to detect and identify syphilis are divided into 
non-treponema! and treponema! tests, on the basis of the antigen used. 
Non-treponema! or lipoid tests involve the use of a non-specific antigen: 
cardiolipin, in combination with lecithin and cholesterol. Treponema! 
tests involve the use of antigens directly derived from treponemata or of 
the entire intact treponema. According to origin, and therefore according 
to specificity in regard toT. pallidum, the tests in this group are further 
divided into group-specific and type-specific treponema! tests. 
This division will be used in a survey of various tests currently per-
formed in The Netherlands, with special reference also to a few new 
modifications not yet introduced here. Two concepts of importance in 
interpreting results of serological tests will also be discussed: anti-
complementarity and biologically false-positive tests. 
3. 2. Non-treponema! tests 
Antibodies demonstrable with the aid of non-treponema! tests used to be 
known as reagins~ These antibodies develop after infection with 
T. pal Jidum, but can also be found in other diseases and during pregnancy. 
They are able to unite with suspensions of lipid extracts of animal and 
vegetable origin, aggregating to form visible masses of the kind observed 
in flocculation tests. These masses are able to unite with complement, and 
this ability underlies the use of the complement fixation test. 
3. 2. 1. Complement fixation tests 
Wasserman et al. ( 1906) were the first to describe the use of a complement 
fixation test with, as antigen, an aqueous extract of livers of foetuses 
deceased from congenital syphilis, in the serological diagnosis of syphilis. 
There followed a long series of modifications, the most important of which 
were the use of aqueous or alcoholic extracts of normal organs as antigen, 
* The term reagin is currently confined to the lgE-class antibodies in 
atopy, and will not be further used here in order to avoid confusion. 
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and addition of cholesterol and lecithin to enhance the sensitivity of the 
test. The procedure described by Kolmer (1922, 1948) is still being used 
as the Kolmer complement fixation test in The Netherlands. This test is 
inexpensive, can be quantitatively performed and permits a high degree of 
automation. 
3. 2. 1. 1. Anti-complementarity 
The term anti-complementarity applies when no haemolysis occurs in the 
control tube of a complement fixation test, i.e. without antigen but in the 
presence of the patient's serum. This phenomenon is often ascribed to 
complement-consuming complexes made up of cryoglobulins, rheumatoid 
factors or large amounts of F-Qlobulins. The repeated occurrence of anti-
complementary serological tests can be indicative of an immunological 
abnormality or affection of the liver (Lassus and Mustakallio, 1973}, and 
therefore always cal Is for further internal examination (Schuller, 1 973; 
Van de Merwe, 1975). 
3. 2. 2. Flocculation tests 
E. Meinicke (1917) was the first to describe a practicable flocculation 
test for syphilis, with the aid of the same antigen as used in the comple-
ment fixation test. Numerous variants of this flocculation test have been 
described in the course of the years. They included the VORL (Venereal 
Disease Research Laboratories) test, which is stilt widely used in The 
Netherlands (Harris, 1946). This test, usually performed as a micro-
flocculation test, can be automated to a large extent. Its advantages in 
comparison with the Kolmer test are rapidity of performance and in-
dependence of a haemolytic system. In 1962, Portnoy et al. described the 
RPR (Rapid Plasma Reagin) card test, performed with the aid of a stable 
VORL antigen suspension which contains carbon particles and which, with 
positive serum, causes flocculation which is readily made macroscopically 
visible by the carbon particles. An important advantage of this test over 
the classical VORL test is simplicity of procedure and availability of a 
distinct and readily readable result within 10 minutes. The RPR card test 
is used in The Netherlands on a limited scare at a few major out-patient 
clinics, particularly as quick screening test. The test can also be per-
formed quantitatively. In recent years, modifications of flocculation tests 
have been developed with special emphasis on automation (ART, Automated 
Reagin Test) and on a more clear readability of the test result. These are 
20 
the Reagin Screen Test (RST}, which makes use of a fat-soluble blue dye, 
and the Syphla-Chek test in which the antigen, conjugated to kaolin and 
choline chloride, gives rise to the formation of light-coloured granules at 
flocculation. In comparison with the RPR card test, the advantages of 
these tests are not evident (Black et al., 1976; Dzink eta/., 1977). 
3. 2. 3. Biologically false-positive tests 
In a number of cases, non-treponema/ tests give a positive result in 
patients in whom a treponema/ infection can be excluded on the basis of the 
medical history, clinical findings and epidemiological data. Serum from a 
person not suffering from treponematosis can contain minute amounts of 
non-treponema/ antibodies (Kahn and Malloy, 1931) that are not demonstra-
ble with the aid of the conventional serological tests. During an infection 
with some other microorganism, this amount can increase sufficiently to 
give rise to a positive non-treponema/ test, usually in low titres. This 
can also occur in auto-immune diseases, after vaccination, during preg-
nancy and in heroin addicts. These so-called biologically false-positive 
tests are further divided, according to the duration of their presence, 
into acute (maximally 6 months) and chronic (exceeding 6 months) biologi-
cally false-positive tests. In view of the fact that" fairly serious diseases 
are occasionally found in patients with chronic biologically false-positive 
tests (Johannsen, 1970; Catterall, 1972; Schuller, 1973), further internal 
examination of these patients is advisable. 
3. 3. Treponema/ tests 
As the limitations imposed on the classical serological tests by the anti-
gen used gradually emerged, the need for tests using treponema-specific 
antigens became more urgent. 
3. 3. 1. Group-specific treponema/ tests 
3. 3. 1. 1. Reiter protein complement fixation test (RPCF test) 
Efforts were made to use the non-virulent Reiter treponema, cultivated in 
vitro, as antigen"!'" Gaehtgens (1929) a/ ready reported good results 
obtained with phenolatea Reiter treponema suspensions. It was subse-
• 
On the basis of comparative studies of the antigenic structure of non-
pathogenic treponemata, Reiter's treponema is now classified as 
T. phagedenis, biotype Reiter. 
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quently demonstrated that this antigen contains only a lipid component, 
which is also responsible for the classical non-treponema! tests (Eagle 
and Hogan, 1940). In an attempt to improve the specificity of antigens 
from Reiter treponema, diAJessandro et al. (1 950) concerned themselves 
in particular with the antigenic structure ofT. reiteri. They isolated a 
protein fraction against which antibodies were demonstrable in syphilis 
patients. This protein antigen proved to react with serum from patients 
with syphilis and other treponematoses, and with Reiter antiserum. It 
was therefore assumed to be a group-specific antigen. A group-specific 
antigen is defined as an antigen which reacts with antibodies against 
several treponema species, i.e. against the causative agents of syphilis 
and other treponematoses as well as non-pathogenic-treponemata. This 
antigen is prepared by precipitating an ultrasonicate of Reiter treponemata 
with 70% saturated ammonium sulphate. It is used in a complement fixation 
test now known as Reiter Protein Complement Fixation (RPCF) test. This 
test is still in use at many laboratories and permits a high degree of 
automation. A disadvantage of the RPCF test is that it sometimes produces 
solitary weak-positive results in the absence of any other indications of 
an infection with pathogenic treponemata. It must be assumed that a cross-
reaction with antigens from non-pathogenic treponemata is involved in these 
cases. Moreover, the occurrence of anti-complementary tests can pose a 
problem. 
3. 3. 1. 2. Reiter protein counter-immuno-electrophoresis (RPCIE) test 
Banffer et al. (1974, 1975) used the Reiter antigen in a counter-immuno-
electrophoresis technique. As advantages they mentioned a higher specifi-
city than the RPCF test and independence of a haemolytic system, thus 
eliminating possible anti-complementarity. 
3. 3. 2. Type specific treponema! tests 
3.3.2.1. Treponema pallidum immobilization (TPI) test 
In the context of an otherwise unsuccessful attempt to evolve a synthetic 
nutrient medium forT. pallidum, Nelson and Steinman (1948) succeeded in 
obtaining a liquid medium in which T. pallidum could survive a number of 
days without multiplying. It was found that serum from syphilis patients 
can contain specific antibodies which, together with complement, are able 
to immobilize virulent T. pallidum (Nelson and Mayer, 1949). This immo-
bilization is microscopically verified. The principle of this Treponema 
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Pallidum Immobilization (TPI) test is simple: virulent T. pallidum micro-
organisms- obtained from inoculated rabbit testes- are mixed with 
patient 1s serum and complement. After 18 hours 1 incubation, the immobili-
zation of the treponemata is microscopically assessed and quantified. 
However, the test is technically complicated and time-consuming, and 
consequently expensive. It is used at only a limited number of laboratories 
in the world (in The Netherlands: the National Institute of Public Health, 
Bilthoven). The specificity of this test proved to exceed that of all other 
tests then available, even though it soon became apparent that even with 
this test it was not possible to differentiate between syphilis and condi-
tions caused by other treponemata, e. g. yaws and pinta. 
Subsequently, numerous efforts have been made to demonstrate treponema! 
antibodies by other techniques and other tests. T repone mal anti gens were 
again used, more specifically dead pathogenic or non-pathogenic trepone-
mata. Due to problems with the production and standardization of stable 
antigens, most of these tests- e. g. Treponema Pallidum Agglutination 
(Magnuson and McLeod, 1956), Treponema Pal I idum Immune Adherence 
(Oiansky et al., 1954) and Treponema Pallidum Complement Fixation 
(Portnoy and Magnuson, 1956) - have not been further developed. 
3. 3. 2. 2. Fluorescent treponema! antibody absorption (FTA-ABS} test 
Deacon, Falcone and Harris in 1957 described a test in which a fluores-
cence technique was used to demonstrate antibodies. This Fluorescent 
Treponema! Antibody (FTA} test made use of intact killed T.pallidum, 
dried on a microscope slide and incubated with a serum dilution (initially 
1:5 but later, in view of many false-positive tests, increased to 1:200}. 
After washing, a fluorescein-conjugated anti-human y-globul in is added, 
and eluted again after incubation. In UV light the treponemata then show 
a bright green fluorescence- at least when antibodies from the patientts 
serum are bound. Hunter et al. (1964) introduced initial absorption of the 
test serum with intact Reiter treponemata. This was based on earlier 
studies (Deacon and Hunter, 1962) which had shown that Reiter trepone-
mata have certain antigenic determinants in common with T. pallidum. 
After absorption the specificity of the test (now cal Jed FTA-ABS test) 
was substantially increased without affecting its sensitivity. Later, a 
different absorbent was used for this purpose: the so-called sorbens, 
which is a concentrate of the supernatant of a heat-killed culture of 
Reiter treponemata(Stoutetal., 1967). This test soon proved to be very 
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sensitive both in untreated and in treated syphilis; in fact its sensitivity 
exceeded that of all other tests then available. Patients with rheumatoid 
factor or other auto-antibodies in the organism occasion-ally show a 
positive FTA-ABS test in the absence of any indication of a treponema! 
infection. Patients with lupus erythematosus likewise often show positive 
fluorescence in the FTA-ABS test; this has a characteristic beaded pattern 
which clearly differs from the homogeneous fluorescence usually observed 
in this test. False-positive FTA-ABS tests have also been described in 
certain other conditions, like diabetes mellitus (Hughes eta!., 1970), 
pregnancy (Buchanan et al., 1970) and herpes genital is (Wright eta!., 
1975). Feeble, not readily interpretable fluorescence patterns are not 
infrequently observed in otherwise quite healthy persons; they may or 
may not be reproducible (Burns, 1975; Dans et af., 1977). 
3. 3. 2. 3. Fluorescent treponema! antibody absorption lgM (FTA-ABS-lgM) 
test 
Scotti and Logan (1968) were the first to describe application of the FTA-
ABS test with a mono-specific conjugate, focused solely on demonstration 
of lgM antibodies. This test proved to be positive in neonates with congen-
ital syphilis, but negative in unaffected infants of mothers with positive 
syphilis tests. The thus demonstrated presence of specific lgM-class 
antibodies might be indicative of active antibody production in the infant, 
in response to an infection with T.paflidum. The sensitivity of the test 
is about 90% in early symptomatic congenital syphilis, but much lower in 
the most common type of congenital syphilis, with later development of 
clinical symptoms: 65%, i.e. lower than the sensitivity of the routine 
FTA-ABS and VORL test (Kaufman et aL, 1974). It was found with the 
aid of this FTA-ABS-IgM test that specific antitreponemal lgM can be 
present, not only in early syphilis but also in untreated latent and late 
forms of syphilis. 
False-positive results may be found in the presence of rheumatoid factor 
(lgM anti-IgG antibodies) in the serum (Wilkinson and Rodin, 1976; 
Shannon and Booth, 1977). Rheumatoid factor can be present in the serum 
of syphilitic adults (Mustakallio et al., 1967; Perrot et al., 1971), but 
also in the serum of neonates with congenital infections. According to 
Reimer et al. (1975), syphilitic neonates produce insufficient amounts of 
lgM antibodies against T.pallidum, but instead produce relatively large 
amounts of lgM anti-lgG antibodies. The presence of maternal lgM in the 
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foetal circulation as a result of materna-foetal transfusion 7 can also 
cause false-positive results. Pollution of the FTA-ABS-lgM reagent 
with lgG can likewise influence the test result (Luger et al., 1977). 
Blockage of the lgM determinants on the antigen surface by excessive 
amounts of lgG antibodies can cause false-negative results (Wilkinson, 
1976; MUller, 1977). Complete separation of lgM and lgG antibodies fol-
lowed by an FTA-ABS-IgM test with only the 195-lgM serum fraction 
substantially enhances the test specificity but for practical reasons cannot 
be used as routine technique (Schmidt, 1979). Both positive and negative 
results of the FTA-ABS-lgM test should be interpreted with caution, and 
the practical value of this test is limited for the time being. 
3. 3. 2. 4. Treponema pallidum haemagglutination assay (TPHA} 
Rathlev (1965) and Tomizawa and Kasamatsu {1966) almost simultaneously 
described the use of a passive haemagglutination technique in demonstra-
ting antibodies against T. pall idum. The technique involves the use of tannin-
treated sheep erythrocytes, sensitized with an ultrasonicate ofT. pallidum. 
The first commercially available version from Japan uses sheep erythro-
cytes. In this test an absorption procedure is carried out with the intention 
of eliminating possible cross-reacting antibodies against sheep erythro-
cytes and non-pathogenic treponemata. Otherwise these cross-reacting 
antibodies might influence the specificity of the test. Sequeira and Eldridge 
{1973) used turkey erythrocytes for the haemagglutination, without preced-
ing absorption. The advantage of this test is that haemagglutination is 
visible within 1 hour of addition of the test serum if it contains antibodies 
{whereas with sheep erythrocytes this takes 4 hours). The TPHA can be 
easily performed as micro-method, and can also be largely automated. 
The test was soon found to be more sensitive than the non-treponema! 
tests. Its important advantage over the FTA-ABS test is easy readability 
without special aids. Its sensitivity seems to be inferior to that of the 
FTA-ABS test in primary syphilis, but may be superior to it in late and 
treated syphilis. The test often remains positive even after treatment 
{perhaps more frequently than the FTA-ABS test). Treatment has no evi-
dent effect on test titres. 
Views on the specificity of this test differ. Blum et al. (1973) found false-
positive TPHA results in a large number of patients, and Ovcinnikov 
(1974) observed many false-positive TPHA results in patients with cancer 
and with various dermatoses. Lesinsky et al .. (1974) concluded that the 
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test specificity, although high in a general population, is substantially 
less than that of the TPI and FTA-ABS tests in patients known to have 
produced biologically false-positive non-treponema! tests. In view of the 
results reported by Tomizawa et al. in Japan (1969), by Garner et al. in 
New Guinea (1973) and by Ghinsberg et al. in Israel (1972), Kiraly and 
Prerau (1974) maintained that the specificity of the TPHA diminishes sub-
stantially when used with sera from patients who come from tropical and 
subtropical regions. Many investigators in Western Europe (O'Neil I et 
al., 1973; Luger and Spendlingwimmer, 1974; Spendlingwimmer, 1976; 
Ehrke et a!., 1977; MUller, 1977) found the specificity of the TPJ-:A to 
equal that of the TPI and the FT A-ABS tests. The different views of 
various investigators on the specificity of the TPHA might be due to the 
presence of certain non-pathogenic treponema in individuals in the popula-
tions studied. 
3. 3. 2. 5. Enzyme immuno-assay (EIA) 
Veldkamp and Visser (1975) were the first to use the Enzyme Immuno-
Assay (EIA) in the serological diagnosis of syphilis. This test involves 
the use of a T.pallidum ultrasonicate with which one coats the wall of a 
test tube or the cup of a microtitre plate. After coating the serum is added. 
With the aid of an anti-human immunoglobulin preparation to which an 
enzyme is attached, the amount of bound immunoglobulin is determined by 
measuring the change of colour which occurs after addition of a substrate 
that is susceptible to the enzyme. An impor-tant advantage of this test is 
that it can be entirely automated, including the reading of results with 
the aid of a spectrophotometer. Although the first results with this test 
have seemed favourable, the specificity of the test will have to be further 
investigated before its routine use can be considered. 
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CHAPTER 4 
AIMS OF THE STUDY 
In the course of a microbial infection 1 different amounts of antibodies 
can be demonstrated at different times with the aid of serological tests. 
We know from practice that this is possible also in syphilis. However, 
the literature supplies no exact data on the course of various serological 
tests for syphilis, performed within a single well-defined population of 
patients. In view of this, the following questions were formulated: 
1. What is the course of a number of non-treponema! serological tests 
(Kolmer, VORL and RPR) and treponema! serological tests (RPCF, 
FTA-ABS and TPI) when a venereally acq...rired infection with 
T. Pallidum is left untreated? 
2a. What is the effect of penicillin treatment on the course of the various 
non-treponema! and treponema! serological tests in patients with 
venereal syphilis? 
2b. Is this course different after two different penicillin treatment courses: 
31.2 million IU on the one hand, and on the other hand 10.8 million IU 
long-acting penicillin distributed over a 6-week period? 
In regional public health laboratories in The Netherlands, several differ-
ent serological syphilis tests are in use. The multitude of tests used, 
often proves to confuse referring physicians; moreover, increasing use is 
made of a new test: the TPHA. In view of this, the fol !owing questions 
were formulated: 
3a. Can the widely used combinations of serological tests (VDRL/Kolmer 
and VDRL/RPCF) be considered effective in the detection of syphilis? 
3b. To which extent could the increasingly used TPHA contribute to this? 
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CHAPTER 5 
MATERIAL AND METHODS 
5. 1. Diagnostic criteria 
The dermato-venereological department of the University Hospital Rotter-
dam, applies the criteria formulated by Menke (1975) for the diagnosis of 
syphi I is, and uses the traditional classification into primary, secondary, 
latent and late symptomatic syphilis. 
5. 1. 1. Primary syphilis 
Primary syphilis is diagnosed when a patient shows a localized skin and/ 
or mucosal lesion as first symptom of infection with T.pallidum, alone or 
in combination with regional lymphadenopathy, and when T. pall idum is 
demonstrated in the lesion or in a lymph node. On the basis of the results 
of the fol towing tests- Kolmer, VDRL, RPCF and TPI -patients with 
primary syphilis are divided into three groups 1 which correspond with the 
following stages: 
a. Sero-negative primary stage (all serological tests are negative). 
b. Sere-changing primary stage (one or more tests are dubious and/or 
positive, but not all tests are simultaneously positive). 
c. Sero-positive primary stage (all tests are positive). 
The FTA-ABS and RPR were not always performed at the time of diagno-
sis of primary syphilis, and therefore are not included in this division. 
5. 1. 2. Secondary syphilis 
Secondary syphilis is diagnosed when a patient shows typical 1 usually 
generalized lesions of the skin and/or mucosa, alone or in combination 
with generalized lymphadenopathy. T. pall idum is sometimes demonstrable 
in material from skin or mucosal efflorescences. Histological findings 
can support or confirm the diagnosis. Serological syphilis tests are 
generally strongly positive. 
5. 1. 3. Early latent syphilis 
Early latent syphilis is diagnosed when a patient shows no clinical skin or 
mucosal lesions, and when anamnestic and/or epidemiological data indicate 
a syphilis infection of no more than 2 years' standing. All serological 
syphilis tests are usually positive. Lymphadenopathy is often present. 
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5.1.4. Early infectious syphilis 
The term early infectious syphilis encompasses primary, secondary and 
early latent syphilis. 
5. 1. 5. Late latent syphilis 
Late latent syphilis is diagnosed when a patient without clinical lesions 
shows positive syphilis tests. A positive TPI is the minimum required. It 
must be plausible on anamnestic and/or epidemiological grounds that the 
infection is more than 2 years old. Internal and neurological examination 
reveals no changes consistent with organic syphilis. Congenital syphilis 
must be excluded on anamnestic and/or epidemiological grounds, supple-
mented if necessary by the results of an extensive physical examination 
including ophthalmological and otological examination, and a family study. 
5. 1. 6. Cardiovascular syphilis 
This diagnosis is established only on the basis of the findings obtained 
by an internist or cardiologist. 
5.1.7. Symptomatic and asymptomatic neurosyphilis 
In patients who have recently or in the past suffer.ed from syphilis, the 
diagnosis neurosyphilis is made on the basis of characteristic changes in 
the cerebrospinal fluid (CSF). The following findings or combinations of 
findings are regarded as characteristic: 
Cel I count exceeding 7/3, total protein exceeding SO mg/1 00 ml, y-globu-
1 in exceeding 20% of total protein, Nonne and/or Pandy test positive, one 
or several serological syphilis tests positive, characteristic abnormal 
course of the gold sol curve. 
The order of sequence of these findings is also a reflection of the typical 
pattern of reaction to invasion pf the central nervous system by T. pallidum. 
These findings are not always associated with clinical neurological changes 
(asymptomatic neurosyphilis). If present, clinical neurological changes 
can range from slight asymmetry of reflexes to a most extensive sympto-
matology, as described in Chapter 2. 
5. 1. 8. Endemic treponematosis 
Endemic treponematosis is diagnosed in patients with positive serological 
syphilis tests (at least TPI positive) and clinical signs of one of the 
endemic treponematoses (yaws, pinta, endemic syphilis), and in patients 
with a history of endemic treponematosis. In patients from regions where 
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endemic treponematoses prevail, who show positive serological syphilis 
tests (TPI positive) but have no history of earlier syphilis or endemic 
treponematosis, no definite diagnosis is made when signs of symptomatic 
syphilis are absent. Both late latent syphilis and latent endemic trepone-
matosis are considered 'possible'. 
5. 1. 9. Congenital syphilis 
Early and late congenital syphilis are diagnosed on the basis of previously 
described characteristic findings at general physical examination and 
dermatological examination, combined with epidemiological data and the 
results of serological testing (see Chapter 2). 
5. 1. 10. Syphilis- not further classifiable 
In a number of cases, insufficient data were available to warrant a defi-
nite diagnosis in retrospect. In a number of these cases, however, it 
could be established with certainty that the patient was suffering from some 
form of syphi I is. These patients were considered to suffer from syphi I is -
not further classifiable. 
5. 1. 11. Possibly syphilis 
Patients in whom one of the above described stages of syphilis was strong-
ly suspected to be present but in whom the diagnosis could not be estab-
lished with certainty due to absence of some anamnestic and/or epidemio-
logical and/or clinical and/or laboratory data, were regarded as 'possi-
bly suffering from syphilis'. 
5. 1. 12. No syphilis 
A number of patients showed a positive result of one or several serological 
tests (with the exception of the TPI), once or repeatedly, although the 
presence of syphilis or another treponematosis could be excluded with 
certainty on the basis of the history, the findings at physical examination, 
and clinical and epidemiological follow-ups. The records of these patients 
were marked 'no syphilis'. 
5.1. 13. Sero-resistance 
The diagnosis •sero-resistance' was made when a syphilis patient, in 
spite of presumably adequate repeated treatments, failed to show at least 
a four-fold decrease of the high pretherapeutic titre of non-treponema! 
antibodies over a follow-up period of at least 2 years. 
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5. 2. Serological testing and laboratory techniques 
5. 2. 1. Serological testing 
Blood samples from all patients involved in the study (covering the period 
from 2nd January 1970 to 30th June 1974) were sent once or several times 
to the Treponema Division of the National Institute of Public Health in 
Bilthoven (heads at the time: Dr J. Bekker until 1st January 1973, and 
Dr J. Veldkamp from 1st January 1973 on) for serological testing. The 
following serological tests were performed at this institute: Kolmer, 
VORL, RPCF, FTA-ABS and TPI (the FTA-ABS test was not performed 
until after 2nd March 1971). The RPR test was always performed at the 
routine laboratory for venereal diseases (head: Prof. Dr M. F. Michel) 
in the dermato-venereological out-patient clinic of the University Hospital 
Rotterdam. The RPR was intended as quick screening test, mostly upon 
suspicion of one of the forms of early infectious syphilis, and was there-
fore carried out in only a limited number of treated patients. 
5. 2. 2. Laboratory techniques 
The VORL flocculation test and the Kolmer complement fixation test were 
performed by the standard techniques described in the Manual of Tests for 
Syphilis (1969), with the following modifications. 
The VORL test was performed qualitatively, the result being described 
by the laboratory as negative, dubious or positive. 
The Kolmer test was performed quantitatively, starting with an undiluted 
series followed by a two-fold dilution series. The results were given as 
titre, titre being defined as the highest reactive serum dilution, i.e. the 
first dilution in which less than SO% haemolysis occurs (DeBruyn, 1957). 
The RPCF test was likewise performed quantitatively, with the aid of 1!U 
complement (DeBruyn and Bekker, 1958). Titration was started with 
undiluted serum. 
The FTA-ABS test was performed as advised in the Manual of tests for 
Syphilis (1969), with the following modifications: serum dilution was 1:12 
instead of 1:5, and the serum was absorbed with an ultrasonicate of T. 
reiteri instead of sorbent. The results were recorded as- (negative), .± 
(dubious), +(weakly positive), or++, +++and++++ (positive) according 
to the degree of fluorescence. 
The TPI test was performed according to Bekker and Onvlee (1955), 
with addition of 100 ,ug lysozyme to the medium (Kent and De Weerdt, 1963). 
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The results were described as negative, dubious or positive, dependent 
on the specific immobilization (Sf) of treponemata in the test. The specific 
immobilization was calculated on the basis of the equation: 
Sl = 100 X 
number of live treponemata in control tube minus number of 
I ive treponemata in test tube 
number of I ive treponemata in control tube 
The TPI test was considered to be positive at Sl >50%, dubious at Sf = 
20-50%, and negative at Sl< 20%. In performing the complement fixation 
test, a reference serum which had been positive in the Kolmer and RPCF 
tests was tested along with the test serum samples. This reference serum 
was supplied by the microbiological reagents division of the National Insti-
tute of Public health, and had been standardized on an international syphi-
1 is reference serum from the WHO reference laboratory in Copenhagen. 
A negative serum was always tested as well. The titre of the reference 
serum remained constant throughout the study period. A positive and a neg-
ative control serum were always included in the qualitative tests VORL, 
FTA-ABS and TPI. These sera were positive/negative also in the comple-
ment fixation test. The RPR test was performed qualitatively in accordance 
with the manufacturer's instructions (Hynson, Westcott & Dunning Inc., 
Baltimore USA); results were recorded as negative(-), weakly positive(+) 
or positive (++), according to the degree of flocculation. 
5. 3. Treatment 
In the course of the period studied, a number of different treatment plans 
were applied. During part of the period, for example, treatment of civil-
ians differed from that of sailors. Moreover, dosage and type of penicillin 
used were changed in the course of the study period. 
5. 3. 1. Civilians 
During the period from 2nd January 1970 to 15th December 1972, civilians 
with sero-positive primary syphilis, secondary syphilis, early latent 
syphilis, late latent syphilis and late symptomatic syphilis were treated 
at the dermato-venereological out-patient clinic of the University Hospital 
Rotterdam. They were given three 6-week penicillin courses with 6-week 
intervals between the courses. The first course consisted of daily intra-
muscular injections of 1. 2 million JU Bicilline® (procaine-penicillin G and 
sodium penicillin G 3:1) during the first two weeks, followed by thrice-
weekly intramuscular injections of 1. 2 mi Ilion IU Penidural DF®(benzathine 
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penicillin G, procaine-penicillin G and potassium penicillin G 2:1:1) 
during four weeks, to a total of 31.2 million IU penicillin. The second 
and the third penicillin course each consisted of twice-weekly intra-
muscular injections of 1.2 million IU Penidural OF® during six weeks, 
to a total of 14.4 million IU penicillin per course. Patients suffering from 
sere-changing primary syphilis were given two penicillin courses, corre-
sponding with the first and the second course described above. Patients 
with sero-negative primary syphilis received only the first course. 
From 15th December 1972 on, the treatment of civilians with primary 
syphilis (regardless of serological status), secondary syphilis, early 
latent syphilis and late latent syphilis was changed to a single course 
of thrice-weekly intramuscular injections of 600.000 IU procaine-penicil-
lin Gin oil with 2% aluminium monostearate. (PAM, Almopen®) during six 
weeks, to a total of 10.8 million IU penicillin. 
5. 3. 2. Sailors 
Sailors were often treated in a clinical setting (Havenziekenhuis, Rotter-
dam; A. P. Djajadiningrat and Dr E. H. Hermans). They received a course 
which consisted of twice-daily intramuscular injections of 600.000 IU 
Almopen® during 15 days, with on the day of departure another 2.4 million 
IU benzathine penicillin G (Penidural®) to a total of 20.4 million IU peni-
cillin. Sailors who could find accommodation in Rotterdam for the duration 
of treatment, were treated in accordance with the routine then followed at 
the dermato-venereological out-patient clinic of the University Hospital 
Rotterdam. 
5. 3. 3. Alternative therapies 
Patients for whom penicillin was contraindicated (usually in view of 
hypersensitivity in the history) were treated with 4 x 500 mg tetracycline 
hydrochloride daily by mouth during 30 days (total dose 60 g); during the 
period from 2nd January 1970 to 15th December 1972, one, two or three 
courses were given on the same indications as penicillin treatment, at 
4-week intervals. Subsequently, a single course was considered suffi-
cient. Patients whose penicillin treatment had to be discontinued (usually 
in view of an allergic reaction) were further treated with tetracycline as 
described above. Patients who developed hypersensitivity or serious 
side effects during tetracycline treatment, were further treated with 
erythromycin by mouth in the same doses as tetracycline. Erythromycin 
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was also prescribed in these doses when penicillin was contraindicated 
during pregnancy. 
5.4. Methods used in collection, registration and processing of data 
The records of all patients first presenting at the dermato-venereological 
out-patient clinic of the University Hospital Rotterdam, between 2nd 
.January 1970 and 30th .June 1974, were systematically examined for 
deviant findings in each of the serological syphilis tests performed. This 
implied that data on patients with sero-negative primary syphilis could 
not be included in the study. In the event of deviant findings, anamnestic, 
epidemiological, clinical, serological and diagnostic data were recorded 
on optical readable forms that had been previously used in studies within 
the dermato-venereological department (Stolz, 1974), and required only 
slight modifications for the purpose of this study. With the aid of an IBM 
1 2 3 4 optical mark page reader linked to an IBM 53 4 card-punching 
unit, the directly readable data were converted to punch-cards (depart-
ment of system development, Faculty of Medicine, Erasmus University). 
Further processing was done at the department of automatic signal pro-
cessing (head: .J. Loeve SSe, programmer R. de Haan) of the Central 
Research Workshops (head: H. A. Bak SSe) of the Medical Faculty, 
Erasmus University, Rotterdam. After transfer of the punch-card data to 
a magnetic disc, all further processing was done with the aid of a PDP 
11/10 computer. Per patient, data were recorded on three different forms, 
numbered A 1, AS and LS. 
A1 form. Epidemiology and basic data (fig. 5.1): 
This form records personal, anamnestic and epidemiological data. 
AS form. Serology (fig. 5. 2)-: 
One AS form was filled out for each date on which serological syphilis 
tests were performed. A gauge-date system indicated the interval be-
tween starting-date and form date in days, weeks, months or years. The 
results of the serological tests were thus recorded per testing date. 
LS form. Diagnosis and treatment (fig. 5 .. 3): 
The diagnosis recorded on the L5 form is the diagnosis established on 
date 0 (starting-date) on the basis of the criteria 1 is ted in section 5. 1. 
Per patient there is one data-set, in which the patient is identified with 
his case record number and starting-date .. The starting-date or date 0 
is the first day of treatment or, if no treatment was given, the day on 
which the first blood sample was obtained .. 
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5. 5. Statistical methods 
Since it was one of the aims of the study to gain an impression of the 
chronological course of the results of a given serological test in a group 
of syphilis patients, an index had to be found to indicate the position of the 
centre of the laboratory data in a number of patients at a particular time. 
The arithmetic mean could not be used for this purpose because it is too 
sensitive to extreme values and therefore would not give an adequate 
characterization of the series of observations. The median was therefore 
used. Since grouped observations were involved, the following equation 
was applied for calculation of the median (Bolle et al., 1973): 
! - FM _ 
Me ~ (XM - ! hM) + --r"-'---'--
M 
Me= median 
hM, in which: 
XM = mid-point of class M, in which the median lies 
hM =class interval of class M 
XM - t hM = the lower bound of class M 
FM- 1 =cumulative relative frequency of class M- 1 
fM = relative frequency of class M. 
With this equation for calculation of the median, a measure of the spread 
of the observations could also be calculated. For this purpose the 25% and 
75% value (1st and 3rd quartile) instead of the SO% value of class M was 
calculated. The equation is consistent also when the consecutive values 
constitute a geometric progression, as is the case with the reciprocal 
values of the tit res (1, 2, 4, 8, etc.) by taking the logarithm with base 2 
from each value. In this way an arithmetic series was obtained which 
could be used to represent the results of titrated tests in a scale division. 
The results of tests which the laboratory describes only as negative, 
dubious, positive or with a number of+ signs, were also represented 
with an arithmetic series. Dubious (~) laboratory results have been re-
garded as valid laboratory findings lying between negative and positive, 
or between negative and titer 1:1. In a scale division with gradation ac-
cording to reactivity of test responses, these were regarded as equidis-
tant (fig. 5. 4). 
The frequency distribution of the titres of non-treponema/ serological 
tests in syphilis patients during and after treatment is known to be log-
normal (Gahlen, 1953; Gahlen and Ninneman, 1965). Logarithmic trans-
formation would make it possible to use tests based on the normal dis-
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tribution in the statistical analysis of the results, but nevertheless we 
applied non-parametric tests. This was done in view of the fact that the 
type distribution of the treponema! tests FTA-ABS and TPI had not been 
established with certainty, and also because the possibility of outlying 
observations made it advisable. 
Wilcoxon's two-sample test was used to compare two groups. When the 
groups were large enough, the normal approximation was used for the 
test statistic. Wilcoxon's signed-rank test was used to compare obser-
vations made within one group on different dates, and the McNemar test 
was applied to compare different tests within one group on the same date. 
The level of significance was always 0. 05. 
The number of observations made per test within one group of patients 
on one gauge-date was arbitrarily set at a minimum of five in order to be 
accepted for further processing. 
5. 6. Graphic representation 
An arithmetic scale division according to disease stage is used in Chapter 
6 and further explained there. The scale division for the various tests is 
shown in fig. 5. 4. The time scale as used in Chapter 7 is given on the 
X-axis. A logarithmic scale has been used for the division according to 
gauge-date (the interval since date 0 being given in days, weeks, months 
or years). With an arithmetic scale, the X-axis would be impractically 
long and there would be an unfavourable effect on accuracy (Ferro, 1954). 
TheY-axis has been divided per test in accordance with the way in which 
the laboratory reported results. The reciprocal values of the titres are 
given. All graphs were drawn by a PDP 11/10 computer with Versatec 
plotter. 
5. 7. Patients 
The total input consisted of data on 1879 patients, recorded on 1879 Al 
forms, 8874 AS forms and 1992 LS forms; 1223 of these patients were 
definitely or possibly suffering from syphilis, while the remainder were 
not suffering from syphilis but showed a deviating serology. Of this re-
mainder, 369 patients had gonorrhoea, and 179 had some other venereal 
disease. AI I further processing was confined to patients who had received 
no antibiotics during the 90 days preceding the first examination. Also 
excluded from further processing were data on all patients who, anam-
nestically or according to records available in the department, had pre-
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viously suffered from one of the forms of early infectious syphilis. 
In each chapter it will be specified which part of the total input was 
studied. 
5. 8. Follow-up of treated patients 
After completion of treatment) blood samples were drawn for serological 
syphilis tests. This was preferably done also 3) 6 and 12 months after 
completion of treatment) and subsequently once a year. In actual practice 
it was not always possible to draw samples on these exact dates; obser-
vations on interim gauge-dates are therefore also mentioned. In some 
cases, several observations were thus made within one gauge-date period. 
In such cases only the last result was considered. 
Two years after treatment for one of the forms of early infectious syphilis, 
patients were examined again in order to exclude possible symptoms of 
late symptomatic syphilis. These follow-ups included clinical neurological 
examination (neurological out-patient clinic, University Hospital Rotter-
dam; for sailors: department of neurology, Havenziekenhuis, Rotterdam) 
including CSF studies (cell count) total protein, y-globulin, Nonne and 
Pandy tests) gold sol curves and serological syphilis tests), a chest 
X-ray and an electrocardiogram. The chest X-ray and the electrocardio-
gram were intended for registration of basic data on the patient involved; 
possible evidence of cardiovascular syphilis cannot be expected until 
much later. 
In actual practice, only a limited number of patients proved to be still 
available for follow-up 2 years after completion of treatment. Some of 
these refused to submit to neurological examination, and this further re-
duced the data available on this part of the follow-up group. The follow-up 
period during which a patient adhered to the above described schedule, 
depended on various imponderables such as change of residence, illness, 
death, departure to foreign countries (sailors), and on a number of factors 
that might to some extent be influenced, e. g. obstinacy and lack of under-
standing on the part of the patient. Although efforts were made to have 
the socio-medical service for control of venereal diseases approach all 
syphilis patients who <Hd not come for follow-ups, the study revealed a 
substantial decrease in the number of patients who did return. 
Of the group of 339 patients with early infectious syphilis (both civilians 
and sailors), only 246 (72%) proved to have returned on gauge-dates 
43-90 (i.e. 43-90 days after institution of treatment). On gauge-date 
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1-1± year they numbered 143 (42.1%), on gauge-date 2-2± years 65 (19.1%) 
and on gauge-date 3-4 years 40 ( 11. 7%). 
Other investigators (Perdrup, 1960; Schroeter eta!., 1972; StOttgen and 
Bartunek, 1973) had similar problems, and likewise lost sight of 50-75% 
of their syphilis patients in the course of a follow-up period of 1-2 years. 
The so-called Blue Star Study - a prospective study of the effect of treat-
ment of syphilis patients with penicillin- was started in the USA in 1945 
(Bauer, 1951). It attempted to continue a follow-up of the largest possible 
number of patients over a long period, and succeeded by virtue of con-
siderable efforts (85.1% of patients were still available for follow-up 
after 8 years) (Shafer eta!., 1954). The course of a number of non-
treponema! serological tests in this group of patients proved to correlate 
well with that in a group of patients less intensively followed, and there-
fore greatly reduced in number in the course of time (lskrant et al., 1951). 
In view of this fact, Iskrant et al. (1951) and Shafer et al. (1954) reached 
the conclusion that patients lost from follow-up for some reason presum-
ably show the same course of serological tests as those who remain avail-
able. 
In the analysis of our personal observations, we proceeded from the as-
sumption that this also applied to the data we collected .. 
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Y-AXIS ' TEST-RESULTS (TITERS GIVEN IN RECIPROKE) 
FOR EXPLANATORY REASONS THE GRADUATION OF THE MEDIAN IS 
SHOWN ON THE INSIDE OF THE X-AXIS 
CHAPTER 6 
THE COURSE OF VARIOUS NON-TREPONEMAL AND TREPONEMAL 
SEROLOGICAL TESTS WHEN AN INFECTION WITH T. PALLIDUM 
IS LEFT UNTREATED 
6. 1. Introduction 
In the course of the development of a bacterial infection both the time of 
appearance and the degree of persistence of antibodies against the caus-
ative agent differ. A large number of factors can be responsible for this: 
1) the microorganism involved is a collection of several antigenic deter-
minants, which differ individually in amount and degree of ability to 
induce an immunological reaction; the antigenic structure ofT. pal!idum 
is very complex and comprises at least proteins, lipids, polysaccha-
rides and lipopolysaccharides; 
2) the portal of entry, the behaviour of the microorganism and its viru-
lence within the host influence the type and degree of antibody forma-
tion; it has been found in test animals that the rate and degree of anti-
body formation upon intratesticular and intraperitoneal inoculation of 
T. pallldum depended on the number of treponemata inoculated (Kent et 
al., 1964). 
3) resistance factors characteristic of the individual patient, and possi-
ble previous infections with T. pa!lidum; 
4} differences between various antibodies which are specific for a given 
antigenic determinant, and differences in sensitivity between the 
various (serological) techniques used to demonstrate the presence of 
antibodies. 
The literature provides only a limited amount of information on the course 
of serological tests in untreated syphilis. Two large groups of syphilis 
patients have in the past remained untreated, and have been systematical-
ly observed during many years following diagnosis. The follow-up 
studies on these groups - known in the I iterature as Boeck's Oslo study 
and the Tuskegee study- have supplied important information on the late 
course of untreated human syphilis in terms of clinical and serological 
aspects of the disease (Bruusgaard, 1929; Gjestland, 1955; Eng and 
Wereide, 1962; Vonderlehr et al., 1936; Olansky eta!., 1956; Rockwell 
et af., 1964}. Olansky (1956) established that in untreated syphilis the 
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change of non-treponema! tests to negative is largely a function of time. 
In patients with untreated syphilis of less than 15 years's standing, for 
example, non-treponema! tests were less frequently found to be negative 
than in older patients with infections of longer standing. This study, and 
other investigations (Eng et al., 1962), revealed that the TPI test fails 
to become negative even after many (sometimes more than 50) years in 
patients with untreated syphilis or with syphilis treated at a very late 
stage. Cutler et al. (1952) left patients with primary sero-negative syph-
ilis untreated for a short period, and described the development of reac-
tivity in a number of non-treponema! tests. They pointed out that a cer-
tain order of sequence is discernible in this development. 
Many investigations have been devoted to evaluation of a newly developed 
serological test or a particular mode of treatment. In the description of 
results, data on the patients' serological status before treatment were 
often reported, although this was not the principal objective of the study 
in question. These studies invariably concerned only a limited number of 
serological tests, performed in often poorly defined or undefined groups 
of patients. In the literature, the results of the various studies are near-
ly always reported as percentage of positive tests (sere-reactivity} with-
out specifying titre or intensity of the reaction. Only a few authors 
(Dandoy, 1967; Sale et al., 1967; Fiumara, 1977; 1978) also supplied data 
on quantitative results of various tests in patients with early infectious 
syphilis. 
For obvious reasons it was impossible to make a longitudinal study of the 
course of serological tests in untreated syphilis patients. We had to 
resort to a cross-section method of investigation, using data obtained in 
retrospect on patients with various stages of syphilis in whom serological 
testing had been done prior to treatment. It was important that the diag-
nosis had been established on the basis of well-defined criteria (see 
Chapter 5) in all these cases, and that several different treponema! and 
non-treponema! tests had been simultaneously performed. 
In this chapter, these data will be used to indicate the course of a number 
of serological tests to be expected if a venereally acquired infection with 
T. pallidum were left untreated. The percentage of sere-reactivity is 
calculated in the same way as the sensitivity of a given test (i.e. the 
percentage of positive or weakly positive results obtained with a given 
test in a given group of syphilis patients). The term sere-reactivity is 
usually used to report the results of an investigation, while the term 
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sensitivity is more frequently used when the value of a given test is dis-
cussed. In this study, too, the serological data obtained before treatment 
in various disease stages are used to compare the sensitivity of the 
various tests. 
6. 2. Material and methods 
The serological data obtained on dateO, i.e. before treatment, were used. 
Table 6. 1 shows the distribution of patients by diagnosis, sex, age (mean 
age±. SO) and civic status (dvilian or sailor). 
The results per test are presented in graphs as indicated in section 5. 6. 
The duration of the infection is given on the X-axis through the various 
corresponding clinical stages. Their place (on the arithmetic scale) has 
been calculated as average interval between the probable moment of in-
fection and the diagnosis. These anamnestic data were available on only 
a limited number of patients. The intervals are indicated in table 6.2 
with the number of patients to whom the data refer. Anamnestic data on 
the probable moment of infection were not available on the patients with 
late latent syphilis and with symptomatic neurosyphilis. 
The graphs are based on the median of the observations made in the 
various groups prior to treatment. Since the data on untreated patients 
were used, these can be accepted as reflecting the course of the results 
of the various tests without the influence of treatment. As a measure of 
the range of the individual observations, the first and the third quartile 
are indicated in the graphs as x 0 _ 25 and x 0 _ 75 , respectively. The results 
are also presented as percentage of sere-reactivity in a tabulated form 
to facilitate comparison with data from the literature. 
6. 3. Resu Its 
6. 3. 1. Percentages of positive tests in untreated patients with 
syphilis in various stages 
Table 6. 3 shows the percentages of positive tests in patients with various 
stages of untreated syphi I is. 
Considering solely the percentage of positive tests, the subgroup of 
sere-changing primary syphilis and the entire group of primary syphilis 
prove to show the following order of decreasing sere-reactivity: 
FTA-ABS > RPR > RPCF > VORL> Kolmer > TPI. 
McNemarrs test was applied to determine the significance of these differ-
ences in sere-reactivity; the results obtained are presented in table 6. 4, 
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which indicates the following order of decreasing sere-reactivity: 
FT A-4BS "' RPR > RPCF"' VCRL > Kolmer"' TPI. 
The differences between FTA-ABS and RPR, between RPCF and VORL 
and between Kolmer and TPI were not statistically significant. 
In secondary syphilis and early latent syphilis, all tests are positive in 
nearly all patients. Considering solely the percentage of positive tests, 
there is hardly any difference between the groups of sero-positive 
primary syphilis, secondary syphilis and early latent syphilis. In the 
group of late latent syphilis, about SO% of patients show a negative 
Kolmer and/or VORL test, 30% have a negative RPR test and almost 
20% show a negative RPCF test. The percentage of positive tests in 
symptomatic neurosyphilis is not distinctly different from that in late 
latent syphilis. 
The significance of differences in sere-reactivity to various serological 
tests in patients with untreated late latent syphilis was likewise studied. 
The results are presented in table 6. 5, which indicates the following 
order of decreasing sera-reactivity: 
TPI "" FT 4-465 > RPCF"' RPR > VDRL"" Kolmer. 
The differences between TPI and FTA-ABS, between RPCF and RPR 
and between VORL and Kolmer were not statistically significant. It is to 
be noted in this context that a positive TPI is one of the criteria of a 
diagnosis of late latent syphilis; the TPI should therefore be positive in 
all these patients. 
6. 3. 2. Graphic representation of the course of serological syphilis tests 
when an infection with T. pall idum is left untreated 
The graphs presented in figures 6. 1 through 6. 6 indicate the course of 
a number of non-treponema! and treponema! serological tests during an 
infection with T. pall idum. The data on which these graphs are based, 
are separately presented per stage and per test in tables 6. 6 through 
6. 11, which also indicate how often a test was not performed and how 
often the serum proved to be polluted, anti-complementary or treponema-
cidal. As already mentioned in chapter 5, not all patients were submitted 
to all tests, and this explains the differences in total numbers. 
In sere-changing primary syphilis and late latent syphilis the range of 
individual observations (x0 . 25 and x 0 _ 75) is wide. A closer look at the 
curves (figs. 6. 1 through 6. 6) reveals a number of differences, per test 
and per group of tests, which can be regarded as characteristic. 
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The non-treponema! tests Kolmer, VORL and RPR show a similar course 
with, more specifically, a rapid increase in reactivity from sere-changing 
primary to sero-positive primary syphilis, followed by a virtually con-
stant positivity up to and including the early latent stage. Next comes a 
more or less marked decrease in reactivity in late latent syphilis, but 
there is no further information on the period of time over which the de-
crease occurs, neither from the I iterature nor from personal observations. 
In sere-changing primary syphilis, the median of the Kolmer and the 
VORL is within the negative range, whereas that of the RPR is a! ready 
within the range of 1+ flocculation. In late latent syphilis, the median of 
the VORL is negative, that of the Kolmer at titre 1:1, and that of the RPR 
at 1+ flocculation. The median of the TPI is negative in sere-changing 
primary syphilis, becomes positive in the sero-positive stage, andre-
mains positive through the later stages. The median of the FTA-ABS is 
already positive (2+ fluorescence) in sere-changing primary syphilis, and 
remains positive through all the stages studied. 
In late latent syphilis the graphs are drawn horizontal. They are not 
connected with the indicated position of the median for symptomatic neuro-
syphilis because only a small part of the patients with late latent syphilis 
will develop symptomatic neurosyphilis. 
In symptomatic neurosyphilis the median of the Komer, VORL and RPCF 
tests is significantly higher than that in late latent syphilis, and TPI and 
FTA-ABS are both positive. 
6. 4. Discussion 
The graphs (figs. 6. 1 through 6. 6) reveal marked differences in the 
course of the various serological syphilis tests in untreated infections 
with T. pallidum. Specifically, there is a marked difference between the 
course of the non-treponemal tests (Kolmer, VORL and RPR) and that of 
the type-specific treponema! tests (FTA-ABS and TPI). The former show 
a rapid increase in the early stages of the infection, followed by a de-
crease to weakly positive (Kolmer and RPR) and dubious {VORL) in the 
late latent stage. The type-specific treponema! tests, however, remain 
positive even in the late latent stage. The RPCF, as group-specific 
treponema! test, would seem to take an intermediate position: there is a 
decrease in late latent syphilis, but less pronounced than that of the non-
treponema! teSts. 
In the literature we found no comparable graphic representation of the 
47 
course of various non-treponema! and treponema! serological syphilis 
tests in untreated infections with T. pat I idum. A pub! i cation of the Center 
of Disease Control, U.s. Public Health Service, USA (VD Program) 
contains a graph which indicates the reactivity of the VORL, FTA-ABS 
and TPI in the course of untreated syphilis (figure 6. 7). This graph is 
based, not on exact data on a group of patients but on impressions con-
cerning the course of the various tests. The use of sere-reactivity in 
the graph gives no information on individual titres or intensity of reac-
tion. Moore (1949) published a graph indicating the course of non-
treponema[ tests in untreated human syphilis in titres (figure 6. 8). This 
author, too, however, mentioned that his graph was merely a hypothetical 
figure, based on 11 impressions and practical experience 11 • 
The studies mentioned in the introduction to this chapter do not distinguish 
between the results of serological tests in sere-changing syphilis and 
those in sero-positive syphilis; nor is the mean interval between the 
moment of infection and diagnosis indicated. Consequently, only data from 
the literature on results of serological tests in patients with primary 
syphilis as a total group could be compared with personal observations. 
In agreement with the findings of other authors (tables 6. 12 through 6. 14), 
the non-treponema! tests were positive in the vast majority of patients in 
all stages of early infectious syphi I is except sere-changing primary 
syphilis. The data from the literature on corresponding tests in the total 
group of primary syphilis, however, show a fair degree of variation 
(table 6. 12). Apart from the fact that the studies originated from different 
laboratories, the diagnostic criteria used were not always strictly de-
fined and similar. The Kolmer and RPR tests were performed and com-
pared with treponema! tests in only a small number of these studies. Our 
own study revealed a higher sensitivity of the RPCF versus the Kolmer 
and VORL in primary syphilis (total group), and a high sensitivity of the 
FTA-ABS and RPR tests; this is in agreement with data from the litera-
ture. The sensitivity of the FTA-ABS in sere-changing primary syphilis 
was found not to differ significantly from that of the RPR. The difference 
in results of various tests between the two stages of primary syphilis 
demonstrates that, without this subdivision (as in the various studies found 
in the literature), a true impression of the course of the reactivity in the 
earliest stages of syphilis cannot be gained. 
In secondary syphilis, all tests were positive in all patients. This is in 
agreement with the data from the literature (table 6. 13). The scanty data 
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from the literature on serological tests in early latent syphilis are listed 
in table 6.14. Our own data on sere-reactivity and titres in patients with 
early latent and late latent syphilis demonstrate- more clearly than is 
apparent from the literature- the possibility of differentiating between these 
stages on the basis of results of non-treponema! tests. This differentiation 
can be of great importance for epidemiology, infectiosity and possible 
development of late symptomatic syphilis. In late latent syphilis, both the 
percentage of sere-reactivity and the median titre of the non-treponema! 
tests show a marked decrease. The treponema! tests (FT A-ASS and TPI) 
show the higi-Jest sero-reactivity in this stage, thus confirming the con-
clusions of studies of long-untreated syphilis patients mentioned in the 
introduction. A striking feature is the high degree of sensitivity of the 
RPR in this stage. Data on this point were not found in the literature. 
The titres of quantitatively performed tests, specifically Kolmer and 
RPCF, show a rapid increase during the primary stage; this persists into 
the secondary stage and is followed by some decrease into the early latent 
stage, when the median titre of the Kolmer is 1:64, while that of the RPCF 
is 1:32. These data are in agreement with the available data from the 
literature (table 6.15). We found no publications reporting on systematic 
studies of the titres of serological tests in patients with late latent syphilis 
and various forms of late symptomatic syphilis. We did find statements 
that the titres of non-treponema! serological tests are generally low in 
late latent syphilis, whereas they can be very high in some forms of late 
symptomatic syphilis, e. g. in dementia paralytica and in late symptomatic 
syphilis associated with gummatous lesions (Stokes et al., 1941; Barniske, 
1957; Orlansky and Norins, 1966). A rise in titre of non-treponema! tests 
in late latent syphilis, therefore, can be indicative of the development of 
one of the forms of late symptomatic syphilis. 
A striking feature is the wide range of test results in late latent syphilis 
and symptomatic neurosyphilis. This could perhaps be explained by the het-
erogeneity of these two groups. The diagnosis 'late latent syphilis 1 is 
made in part arbitrarily: the infection must have existed more than two 
years. Theoretically, this implies that this group can include patients 
whose infection was acquired 2! years ago as well as patients who ac-
quired it 30 years ago. Apart from this, patients with late latent syphilis 
showing high titres of non-treponema! tests may include some individuals 
in the process of developing a not yet diagnosed late symptomatic syphilis. 
Patients with symptomatic neurosyphilis can differ in activity of the 
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infection and therefore possibly also in amount of antibodies demonstrable 
with the aid of non-treponema! tests. 
Of the patients with late latent syphilis, 1 t% had a negative TPI test. This 
seems to contradict the previously mentioned criterion of a positive TPI 
for a diagnosis of late latent syphilis. In actual practice, however, one 
finds that the TPI can give varying results in late latent syphilis, and 
in some patients can vary between negative, dubious and weakly positive. 
For a test result reported as negative, the immobilization percentage in 
such cases is often found to be just below 20% (personal observation). 
Serological testing is repeatedly done in cases in which late latent syphilis 
is considered possible. It is consequently possible that the diagnosis is 
ultimately made partly in view of a positive TPI, even though this test was 
negative on the date of processing the test results. Obeid-Ruggli (1960) 
even described this fluctuation of the results of serological tests as char-
acteristic of late latent syphilis. 
An illustration of the possible influence of a testing technique is found in 
the already mentioned higher sensitivity of the RPR versus the VORL test. 
Exactly the same (VORL) antigen (Manual of tests for syphilis 1969) is 
used in exactly the same amounts in both tests. The principal technical 
difference between the two tests is that in the RPR carbon particles are 
added to the antigen solution, which co-agglutinate when flocculation oc-
curs. This co-agglutination is readily visible macroscopically. In the 
VORL1 the degree of agglutination is microscopically assessed, without 
any special marker. 
6. 5. Conclusions 
Regarding the course of serological syphilis tests in untreated infections 
with T. pall idum, a number of microbiological principles apply also to 
syphilis. This applies in particular to some factors mentioned in the intro-
duction, e. g. diversity of antigens, diversity of antibodies formed, and 
differences in serological techniques used. 
An exact graphic representation of the course of several different sero-
logical syphilis tests, using data on well-defined groups of patients and 
subdivided according to disease stage, gives insight into the value of the 
various tests and may be helpful in the interpretation of results of sero-
logical tests in untreated patients. This type of representation also makes 
it possible to compare the sensitivity of the various tests in various stages 
of the disease. In primary syphilis, the VORL test was significantly more 
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often positive than the Kolmer, and the following order of decreasing 
sensitivity was found: 
FTA-ABS"" RPR > RPCF"" VORL> Kolmer"' TPI. 
It was found that about SO% of the patients with late latent syphilis had a 
negative Kolmer and/or VORL test; 30% had a negative RP.R, and nearly 
20% had a negative RPCF test. In late latent syphilis, the following order 
of decreasing sensitivity was found: 
TPI"" FTA-ABS > RPCF"' RPR >VORL"' Kolmer. 
In one of the most important forms of late symptomatic syphilis- sympto-
matic neurosyphilis- it was found that the titres of non-treponema! tests 
can be substantially higher than those in late latent syphilis. When high 
titres are found in non-treponema! tests in patients with serological, 
anamnestic and/or epidemiological indications of syphilis acquired many 
years earlier, or when titres of non-treponema! tests rise in patients 
with late latent syphilis, late symptomatic syphilis should be eliminated. 
The importance of repeated serological testing of patients showing no 
clinical symptoms of one of the forms of early syphilis, was demonstrated 
by the fact that- in a small proportion of the patients with late latent 
syphilis- repeated TPI tests before treatment were not constantly posi-
tive. The above described pattern of a successive turning positive of the 
various tests in primary syphi I is I ikewise provides an argument in favour 
of repeated serological testing of patients suspected of syphilis. 
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Table 6.1 
"' Distribution of patients by diagnosis, sex, age (mean age ±SO) and civic status (civilian or sailor) 
men women 
civilians sailors 
number mean age so number mean age so number number 
in years in years 
sera-changing 110 30.1 9.0 6 31.4 8.8 67 69 
primary syphilis 
sero-positive 44 31.6 9.8 4 26 6.9 27 21 
primary syphilis 
secondary syphilis 67 31.5 11.0 27 29 9.5 70 24 
early latent syphilis 57 32.4 7.5 21 24.7 4.5 53 25 
late latent syphilis 81 46.7 15.2 51 48.2 14.3 114 18 
symptomatic neurosyphilis 20 56.2 13.7 4 52.2 14.6 23 
Table 6.2 
Interval between moment of infection and diagnosis 
stage of disease 
primary syphilis 
sera-changing; n = 44 
primary syphilis 
sero-positive; n = 1 7 
secondary syphilis 
n = 35 
early latent syphilis 
n = 19 
Table 6.3 
number of days 
(mean) 
31.9 
41.0 
91.0 
225.8 
Percentage of positive tests in patients with untreated syphilis 
number of 
patients Kolmer VDRL RPR RPCF 
primary syphilis 
sera-changing 116 35.0% 48.2% 83.3% 52.2% 
primary syphilis 
sero-positive 48 100% 100% 97.5% 100% 
primary syphilis 
total group 164 54.3% 63.4% 87.5% 66.4% 
secondary syphilis 94 100% 100% 100% 100% 
early latent 
syphilis 78 100% 98.7% 100% 94.8% 
late latent 
syphilis 132 52.9% 47.5% 69.2% 81.8% 
symptomatic 
neurosyphilis 24 68.2% 52.2% 95.5% 
SD 
13.5 
14.6 
27.4 
109.7 
FTA-
TPI ABS 
23.3% 90.0% 
100% 100% 
46.0% 91.7% 
99.0% 100% 
96.4% 100% 
89.1% 94.1% 
94.1% 93.7% 
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Table 6.4 
Comparison of percentages of sero~reactivity in different serological tests in patients with untreated 
primary syphilis (McNemar's test) 
NS == not significant 
p 
VORL Kolmer < 0,01 
RPCF Kolmer < 0,01 
FTA-ABS Kolmer < 0.001 
TPI Kolmer NS 
RPR Kolmer < 0.001 
RPCF VORL NS 
FTA·ABS VORL < 0.001 
TPI VORL < 0.001 
RPR VDRL < 0.001 
FTA-ABS RPCF < 0.001 
TPI RPCF < 0.001 
RPR RPCF < 0.001 
TPI FTA·ABS < 0.001 
RPR FTA-ABS NS 
RPR TPI < 0.001 
Table 6.5 
Comparison of percentages of sero~reactivity in different serological tests in patients with untreated 
late latent syphilis (McNemar's test) 
p 
VORL Kolmer NS 
RPCF Kolmer < 0.001 
FTA-ABS Kolmer < 0.001 
TPI Kolmer < 0.001 
RPR Kolmer < 0.05 
RPCF VORL < 0.001 
FTA-ABS VORL < 0.001 
TPI VORL < 0.001 
RPR VORL < 0.10 
FTA-ABS RPCF < 0.02 
TPI RPCF < 0.05 
RPR RPCF NS 
TPI FTA-ABS NS 
RPR TPI < 0.02 
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Table 6.6 
Results of serological tests in patients with sero-changing primary syphilis prior to treatment 
Kolmer 
neg dub 2 4 8 16 32 64 128 256 512 nd ac tot Xo.2s Me Xo.75 
74 0 6 4 8 6 6 4 4 0 2 114 0.5 0.8 4.0 
VORL 
neg dub pos nd tot x 0 .2s Me Xo.75 
60 12 44 0 116 0.5 0.9 2.3 
RPCF 
neg dub 2 4 8 16 32 64 128 256 512 nd ac tot xo.2s Me Xo.7s 
54 1 12 4 19 13 5 3 2 0 0 0 1 2 113 0.5 2.1 4.7 
FTA-ABS 
neg + + ++ +++ 4+ nd tot Xo.2s Me Xo.75 
------------------------------------------------------------------
7 4 
TPI 
neg dub 
82 
APR 
neg + 
8 
16 35 
19 
pos 
17 
++ 
45 
37 2 1 
trep nd ac 
2 4 
nd 
20 
46 70 2.3 3.1 3.6 
tf tot Xo.2s Me Xo.75 
2 107 0.5 0.6 1.0 
tot Xo.25 Me xo.75 
96 1.2 1.9 2.5 
<.n Table 6. 7 
"' Results of serological tests in patients with sero·positive primary syphilis prior to treatment 
Kolmer 
neQdub 
0 0 
VDRL 
2 4 8 
5 6 
neg-dub pas nd 
0 0 
RPCF 
neg- dub 
0 0 
FTA-ABS 
neg + 
0 0 
TPI 
neg dub 
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2 
+ 
8 
pos 
0 
2 4 8 
4 10 6 
++ +++ 4+ 
19 0 0 
trep nd ac 
16 32 64 128 256 512 
4 5 10 11 2 3 
16 32 64 128 256 512 
5 9 4 8 0 0 
nd 
21 
tf 
nd ac tot x0.25 Me Xo.75 
0 0 48 6.2 8.4 9.6 
tot Xo.25 Me Xo.75 
48 2.3 2.5 2.8 
nd ac tot Xo.25 Me Xo.75 
0 0 48 4.6 6.4 8.3 
tot Xo.25 Me xo.75 
27 3.0 3.3 3.7 
tot Xo.25 Me Xo.75 
------------------------------------------------------------------
0 
APR 
neg 
8 
+ 
7 
37 
++ 
32 
0 3 0 0 
nd 
8 
45 2.1 2.4 2.5 
tot Xo.25 Me xo.75 
40 2.1 2.4 2.5 
"' 
.., 
Table 6.8 
Results of serological tests in patients with secondary syphilis prior to treatment 
Kotmer 
negdub 
0 0 
VORL 
2 
0 0 
~dub pos nd 
0 93 
RPCF 
neg dub 2 
0 0 0 
FTA·ABS 
4 8 
0 
4 8 
7 5 
neg + + ++ +++ 4+ 
0 0 24 29 
TPI 
neg dub pas trep nd 
RPR 
neg + 
0 12 
80 
++ 
54 
0 10 
nd 
29 
ac 
3 
16 32 64 128 256 
3 3 20 21 25 
16 32 64 128 256 
8 20 19 34 0 
nd 
40 
tf 
0 
512 nd ac tot xo.25 Me Xo.75 
30 93 9.3 10.3 11.2 
tot Xo.25 Me Xo.75 
94 2.2 2.5 2.5 
512 nd ac tot Xo.25 Me Xo.75 
0 0 94 7.1 8.3 9.3 
tot Xo.25 Me Xo.75 
55 2.6 3.1 3.6 
tot Xo.25 Me xo.75 
82 2.2 2.5 2.5 
tot Xo.25 Me xo.75 
66 2.1 2.4 2.7 
~ Table 6,9 
Results of serological tests in patients with early latent syphilis prior to treatment 
Kolmer 
neg-dub 
0 0 
VORL 
2 
2 
neg-dub pos nd 
2 74 
RPCF 
neg dub 2 
4 0 1 2 
FTA·ABS 
neg +- + ++ 
4 
4 
4 
2 
+++ 
8 16 32 64 128 256 
7 8 11 22 9 9 
8 16 32 64 128 256 
9 14 17 20 8 0 
4+ nd 
512 nd ac tot Xo.25 Me Xo.75 
4 0 77 6.7 8.3 9.3 
tot Xo.25 Me xo.75 
77 2.2 2.5 2.5 
512 nd ac tot Xo.25 Me Xo.75 
0 1 0 77 6.1 7.4 8.4 
tot Xo.25 Me Xo.75 
------------------------------------------------------------------
0 0 
TPI 
neg dub 
2 
RPR 
neg + 
0 
0 
5 
14 27 4 4 
pos trep nd ac 
54 0 21 
++ nd 
30 43 
29 79 2.9 3.4 3.8 
tf tot Xo.25 Me Xo.75 
0 56 2.2 2.5 2.5 
tot Xo.25 Me Xo.75 
35 2.1 2.4 2.5 
~ 
Table 6.10 
Results of serological tests in patients with late latent syphilis prior to treatment 
Kolmer 
neg-dub 
55 0 
VDRL 
9 
2 4 8 
15 8 12 
neg dub pos nd 
64 9 
RPCF 
neg dub 
21 2 
FTA-ABS 
neg + 
4 4 
TPI 
neg dub 
49 
23 
+ 
20 
pos 
10 
2 4 8 
25 17 18 
++ +++ 4+ 
37 3 0 
trep nd ac 
16 32 64 128 256 
9 4 2 2 
16 32 64 128 256 
3 4 3 0 0 
nd 
64 
tf 
512 nd ac tot Xo.25 Me x0.75 
0 9 6 117 0.5 2.4 5.1 
tot x0.25 Me Xo.75 
122 0.5 1.0 2.4 
512 nd ac tOt x0.25 Me Xo.75 
0 8 8 116 2.3 3.5 4.9 
tot Xo.25 Me Xo.75 
68 2.5 3.2 3.6 
tOt Xo.25 Me Xo.75 
------------------------------------------------------------------
9 6 
RPR 
neg + 
12 11 
68 
++ 
16 
45 3 0 
nd 
93 
83 2.1 2.4 2.5 
tot x0.25 Me Xo.75 
38 0.8 1.7 2.4 
~ Table6.11 
Results of serological tests in patients with symptomatic neurosyphilis prior to treatment 
Kolmer 
neg-dub 
7 0 
VDRL 
2 
2 4 8 
0 0 
neg-dub pos nd 
11 0 
RPCF 
neg dub 
FTA·ABS 
neg + 
TPI 
neg dub 
12 
7 
+ 
6 
pos 
2 4 8 
0 
++ +++ 4+ 
8 0 0 
trep nd ac 
16 32 64 128 256 512 
0 3 3 3 2 
16 32 64 128 256 512 
5 4 0 0 
nd 
8 
tf 
nd ac tot x 0.25 Me Xo.75 
22 0.8 7.3 9.8 
tot Xo.25 Me Xo.75 
23 0.5 2.0 2.5 
nd ac tot Xo.25 Me Xo.75 
22 2.5 5.0 7.9 
tot x0.25 Me Xo.75 
16 2.3 3.0 3.5 
tot Xo.25 Me Xo.75 
------------------------------------------------------------------
15 0 6 1 0 17 2.2 2.4 2.7 
RPR 
neg + ++ nd tot Xo.25 Me xo.75 
insufficient data 
Table 6.12 
Percentage of positive tests (sera-reactivitY) in patients with untreated primary syphilis 
number 
of FTA-
patients Kolmer VORL RPR RPCF TPI ABS 
Edmundson et al. (1954) 30 50.0'% 33.0% 
Cannefax eta!. (1957) 140 61.4% 25.7% 
Moore eta!. (1965) 76 50.0% 48.7% 36.8% 80.7% 
Deacon et al. (1966) 103 75.7% 53.4% 86.4% 
Knox et al. (1966) 37 80.0% 57.0% 87.0% 
FOrstrOm et al. (1967) 128 76.0% 66.0% 50.0% 24.0% 
Lassus et al. (1967) 62 77.0% 63.0% 28.0% 15 .0"/o 84.0"1<1 
Dandoy (1967) 97 74.4% 71.2% 
Salo et al. (1967) 112 41.0% 31.2% 
T;o (1970) 115 47.0% 42.0% 63.0% 67.0% 
Duncan et al. (1974) 77 73.0% 91.0% 
Dijckman et al. (1976) 111 63.1% 64.1% 94.6% 
Table 6.13 
Percentage of positive tests in patients with untreated secondary syphilis 
number 
of FTA-
patients Kolmer VORL RPR RPCF TPI ABS 
Cannefax eta!. (1957) 117 84.6% 72.6% 
Sera--studie (1959) 91 100% 100% 98.9% 100% 
Hederstedt et al. (1964) 23 100% 100% 
Falcone et al. (1964) 217 100% 97.2% 
Brown et al. (1964) 148 100% 100% 
Moore et al. (1965) 100 100% 100% 
Knox et al. (1966) 41 100% 100% 100% 
Deacon et al. (1966) 121 100% 98.3% 99.2% 
Lassus eta!. (1976) 14 100% 100% 100% 100% 100% 
FOrstrOm (1967) 65 100% 100% 89.0% 90.0% 
Salo et al. (1967) 51 72.5% 88.2% 
Dandoy (1967) 84 100% 98.8% 
Tic (1970) 43 93.0% 95.0% 100% 100% 
Dijckman et al. (1976) 56 100% 100% 100% 
Table 6.14 
Percentage of positive tests in patients with untreated early latent syphilis 
number 
of FTA-
patients Kolmer VORL RPR RPCF TPI ASS 
Magnuson eta!. {1949) 106 98.3% 99.1% 
Chester et al. {1953i 172 100% 
Cannefax etal. {1957) 159 86.1% 88.3% 
Dandoy eta!. (1967) 67 98.4% 95.5% 
Fiumara (1978) 275 100% 100% 
61 
~ Table 6.15 
Results of quantitatively performed serological tests in various stages of syphilis 
titre 
primary syphilis 
secondary syphilis 
early latent syphilis 
VORL 
(Dandoy, 1967) 
<;;1/8 >1116 
67.0% 33.0% 
10.7% 89.2% 
44.7% 55.2% 
Kolmer 
(Dandoy) 
~1/8 ~1/16 
47.6% 52.3% 
4.1% 95.8% 
25.0% 75.0% 
RPCF 
(Salo e.a. 1967) 
~ 1/8 > 1/16 
81.2% 18.7% 
35.2% 64.7% 
RPR 
(Fiumara 1977) 
<;;1/8 >1116 
65.3% 34.7% 
50.9% 49.1% 
FTA·ABS 
(Fiumara 1978) 
2+ 3+ 
24.4% 75.6% 
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CHAPTER 7 
INFLUENCE OF PENICILLIN TREATMENT ON THE COURSE OF 
VARIOUS NON-TREPONEMAL AND TREPONEMAL SEROLOGICAL 
TESTS IN PATIENTS WITH ACQUIRED SYPHILIS 
7. 1. Introduction 
An important objective in the treatment of syphilis (apart from controlling 
acute disease symptoms and eliminating infectiousness) is the prevention 
of late forms of syphilis, and more in particular of the various forms of 
late symptomatic syphilis. 
Criteria for evaluation of the effect of treatment in syphilis patients are 
limited. In primary and secondary syphilis, the disappearance of the 
clinical symptoms can serve as criterion. It should be borne in mind, how-
ever, that these symptoms also disappear when the patient is left untreated. 
This spontaneous disappearance of symptoms is followed in 25% of these 
patients by spontaneous recurrences within the first year. The prevention 
of these recurrences could be a criterion for the effect of treatment. The 
prevention of late symptomatic syphilis might also be used as a criterion 
for the effect of treatment, but studies in this respect are impeded by the 
long period of observation required. 
In follow-ups on treated syphilis patients, serological tests often prove 
to have the greatest practical importance, both for the doctor and for the 
patient. In latent syphilis, a possible decrease in reactivity of serological 
tests is in fact the only direct parameter for the effect of the treatment 
instituted. In order to avoid superfluous re-treatment of a previously 
treated patient solely on the basis of serological test results, an insight 
into the likely course of serological syphilis tests after treatment is re-
quired. 
The extent to which the results of a serological syphilis test can be in-
fluenced by treatment of a syphilis patient, is probably dependent on sev-
eral factors, e. g. 1) the stage of the disease at the time of treatment (i.e. 
the duration of the infection and the possible development of immunity), 
2) the type of serological test performed, and 3) the type of treatment pro-
vided. 
Soon after publication of the first description of a serological test which 
could be effectively used in diagnosing syphilis, it was reported that the 
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intensity of the reaction varied with the stage of the disease (Landsteiner 
et al., 1907), and that in many cases the Wassermann complement fixation 
test quickly became negative in response to treatment. 1t was also noted 
that the extent to which the reactivity of a serological syphi I is test can be 
influenced, is dependent on the stage of the disease at the time of treatment. 
The same was reported for other, subsequently evolved non-treponema! 
serological syphilis tests (Rein, 1947; Shafer et al., 1954; Huriez and 
Dujardin, 1959). When the first treponema! test was introduced (TPI test), 
its reactivity was found to be often less quickly influenced by treatment 
than that of non-treponema! tests (Crampon and Baelden, 1952; Moore and 
Mohr, 1952; Jaeger and Delacretaz, 1953; Miller et al., 1954). The same 
proved to apply to the FT A-ABS test (Deacon et a!. , 1966; Wood et al. , 
1967; Atwood et al., 1968; Harner et al., 1968; Hunter et al., 1968; 
Schroeter et a!., 1972; Hunter, 1975). 
Different serological tests can show differences in sensitivity, which in 
part are inherent to the method used and their basic principle. A study 
of the spontaneous course of the results of several serological tests re-
vealed a distinct difference in the tendency to decrease in reactivity be-
tween the non-treponema! tests (Kolmer, VORL, RPR) and type-specific 
treponema! tests (TPI, FTA-ABS). It seems plausible that influences 
which determine this difference between non-treponema! and treponema! 
tests play a role also in the decrease in reactivity which may occur in re-
sponse to treatment. 
In the course of the first few years after the introduction of penicillin in 
the treatment of syphi I is (Mahoney, 1944), numerous treatment pi ans were 
used of which some, in retrospect were certainly not consistent with the 
basic principles of penicillin treatment for syphilis as mentioned in sec-
tion 2. 10. Therapies not consistent with these principles (Bauer et al., 
1947; Barton et al., 1949; Plotke et al., 1951) invariably produced poor 
results, more specifically a very slow fall of the titres of non-treponema! 
tests, and a high relapse rate of clinical symptoms. Nevertheless, even 
after the definition of these principles of penicillin treatment for syphilis 
there continued to be substantial differences between the treatment plans 
used in different countries and at different institutes. 
Guthe and ldsoe (1968) and ldsoe et al. (1972) published monographs on all 
results obtained by various therapies as reported by (mainly European) 
investigators, at least so far as the studies in question fulfilled a number 
of minimum requirements concerning definition of syphilis stages and 
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therapy used. Both the serological (tests becoming negative) and the clin-
ical results were assessed in these studies. A striking finding was that 
few studies mentioned results of treponema! tests after treatment. 
The Center for Disease Control, Venereal Cisease Control Division, Pub-
lic Health Service of the American Ministry of Public Health in Atlanta 
(Thompson et al., 1976) likewise published a comprehensive study of Amer-
ican and English literature on results obtained by various therapies. It 
was concluded that the efficacy of therapies advised by the WHO for prima-
ry syphilis requires further investigation, although no direct evidence was 
found which indicated the necessity of immediate changes in these recom-
mendations. The question whether there are differences in relative effica-
cy between the therapies recommended for primary and secondary syphilis, 
and/or whether an increase of the recommended dosage would enhance effi-
cacy, could not be answered. Cue to deficient data from the literature, it 
could only be recommended that latent syphilis be given more intensive 
therapy than that advised for primary or secondary syphilis. 
This chapter discusses the influence of penicillin treatment on the course 
of a number of non-treponema! and treponema! serological syphilis tests, 
on the basis of serological data obtained in retrospect at different inter-
vals after treatment in a number of well-defined groups of patients with 
various stages of syphilis. The question whether the course of the sero-
logical tests differs after two different therapies is also discussed. 
7. 2. Material and methods 
The total groups per diagnosis (sere-changing primary syphilis, sero-
positive primary syphilis, secondary syphilis, early latent syphilis and 
late latent syphilis) were subdivided according to treatment given (table 
7.1). As already mentioned in Chapter 5, some of the patients were given 
more than one course of penicillin treatment, dependent on the results of 
serological tests prior to treatment. In these cases the first course of 
31.2 million IU penicillin was followed by a second and sometimes by a 
third course of 14.4 million lU penicillin. These subgroups comprised 
only small numbers of patients per treatment and per diagnosis. It was 
therefore decided for further analysis to regard patients treated with 
31.2 million IU, those given 31.2 + 14.4 million IU, and those given 31.2 
+ 14.4 + 14.4 million IU, as a single group treated with a minimum of 
31.2 million IU penicillin over a minimum period of 6 weeks. 
On 15th December 1972, ·i.e. during the period covered by this study, 
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this high-dosage penicillin therapy (still based on the so-called Bonner 
salvarsan cures) was abandoned in favour of a course of Jess large doses 
of penicillin (10.8 million lU over 6 weeks). This made it.possible to com-
pare these two therapies. On the patients (sailors) treated at the 1-\aven-
ziekenhuis, Rotterdam (A. P. Cjajadiningrat and Dr E. H. Hermans) with 
20.4 million IU penicillin during 14 days, few serological data were avail-
able because these patients often departed shortly after release from 
hospital. Only the pretherapeutic data on these patients were used in anal-
ysis. 
The study confined itself to the course of serological tests: Kolmer, VDRL, 
RPCF, FTA-ABS and TPI. Within the period of observation, possible 
differences in development of late symptoms of syphilis could not be studied. 
'The data on the patients treated with tetracycline, and those on the patients 
who departed without receiving treatment, were not further analyzed be-
cause the numbers involved were too small. 
In the discussion of results of serological tests after treatment, the term 
sero-negativity is used to make comparison with the literature possible. 
This term refers to the percentage of patients with negative serological 
findings at a given time. 
The patients described above include none with sero-resistance. The data 
on these patients were separately grouped for computer input under this 
diagnosis (these patients numbered a total of 14). 
7. 3. Results 
7. 3. 1. Graphic representation of the course of various serological 
syphilis tests in response to penicillin treatment, regardless 
of the dosage and duration of treatment 
Figures 7.1 through 7. 5 show the course of the serological tests perform-
ed during and after penicillin treatment of patients with various stages of 
syphilis. The tests were performed over a period which ranged from a 
minimum of 2 to a maximum of 5 years after treatment. Tables 7. 2 through 
7. 6 indicate the number of observations and the value of the median per 
diagnosis, per test and per gauge-date. For a number of gauge-dates 
which can be compared with the literature, moreover, the percentage of 
sero-negative patients was calculated. The results will be discussed per 
diagnosis and per test. 
70 
7. 3. 1.1. Sere-changing primary syphilis (table 7. 2; figs. 7.1 through 7. 5): 
.t<.e..l!!l~ 
Before treatment, the median is within the negative range, the test being 
negative in 65% of patients; 6-7 months after treatment, the test is nega-
tive in 100% of patients. 
YQ13.L,_ 
Before treatment, the median is within the negative range, the test being 
negative in 53% of patients; 6-7 months after treatment, the test is nega-
tive in all patients. The increase in the median of the VORL observed 
8-21 days after institution of treatment is statistically significant 
(Wilcoxon's signed-rank test, right-sided). 
BE' f.~ 
Before treatment, the median is at titre 1:1 and, like that of the VORL, 
it increases 8-21 days after institution of treatment. This increase is not 
statistically significant. The test is negative in all patients investigated 
10-12 months after start of treatment. 
fi6-.t-E?s 
Before treatment, the median is already within the range of 2+ reactivity, 
the test being still negative in 10% of patients. The median decreases 
after treatment, and 33% of patients have a negative test after 6-7 months. 
The median is negative 10-12 months after treatment; 19-24 months after 
treatment, the test is negative in 73% of patients. All patients still avail-
able for follow-up 2-k-3 years later show a negative FTA-ABS test. 
TPI 
Before treatment, the median is within the negative range. Sero-negativi-
ty increases from 77% before treatment to 92% 6-7 months after treatment. 
It is 100% in the patients still available after 10-12 months. 
7.3.1.2. Sero-positive primary syphilis (table 7.3; figs. 7.1 through 7.5): 
!<£1!!:J~ 
The median before treatment is at titre 1 :64 and decreases to negative 
within 4-5 months. Sero-negativity is 83% after 6-7 months, but does not 
attain the 100% level until after 19-24 months. 
YQ13.L,_ 
The median remains virually unchanged and positive during the first few 
weeks after treatment. Sero-negativity (0% before treatment) increases 
to 28%. The median decreases to negative after 4-5 months. Sero-nega-
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tivity increases to 87% after 6-7 months, and is 100% of all patients still 
available after 19-24 months. 
BE'£F:. 
The median decreases from titre 1:16 before treatment to negative after 
8-9 months, when sero-negativity is 60%. Sero-negativity increases to 
75% 2-2! years after treatment. 
£'I ~-.8§!2. 
The median lies within the range of 2+ before treatment, and gradually 
decreases to the range of 1+ after 19-24 months, when sero-negativity is 
15%. The median is negative after 2-2i years, when sero-negativity is 
62%. Not in all patients with sero-positive primary syphilis did the FTA-
ABS test become negative within the period of observation (2! years) . 
.:TE'l 
The median varies between positive and dubious during the first 4-5 months 
after treatment. Sero-negativity after 43-90 days is SO%. The median is 
negative after 6-7 months, and sero-negativity is 80% after 2-2i years. 
7.3.1.3. Secondary syphilis (table 7.4; figs. 7.1 through 7.5): 
.!.<£1!:!:1~ 
The median before treatment is at titre 1 :256 and becomes negative after 
6-7 months, when sero-negativity is 51%. This subsequently increases to 
95% 3-4 years after institution of treatment. 
Yfll3_t.,_ 
The median is negative after 8-9 months; sero-negativity is 93% after 
10-12 months, and 89% after 3-4 years 
BE'£F:. 
The median decreases from titre 1:64 to 1:1 after 13-18 months, when 
sero-negativity is 30%. Sero-negativity 3-4. years after treatment is 21%. 
£'I ~-£-.§!2. 
The median fails to decrease over the period of observation (3-4 years), 
but sero-negativity shows some slight increase, ranging from 5% to 10% 
after 10-12 months . 
.:TE'!. 
The median decreases to negative 2!-3 years after treatment, while sero-
negativity increases from 32% after 10-12 months to 70% after 3-4 years. 
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7.3.1.4. Early latent syphilis (table 7.5; figs. 7.1 through 7.5): 
.!.<2.1 !:!:)~ 
The median decreases from titre 1:64 to negative after 13-18 months 7 when 
sero-negativity is 53% . 
.YQ'3.l:. 
The median is positive before treatment and decreases to negative after 
1 0-12 months. Sero-negativity is 0% before treatment, 60% after 1 0-12 
months and sti II 60% after 3-4 years. 
BE'£F:. 
The median decreases from titre 1:32 before treatment to 1:4 after 6-7 
months, but does not become negative within the period of observation 
(3-4 years). Sero-negativity is 5% before treatment and 10% after 3-4 
years . 
.EI6-:8§§. 
The median is at 2+ before treatment and hardly changes throughout the 
period of observation (3-4 years after treatment). Sero-negativity remains 
0%. 
TPI 
The median is positive before treatment and hardly changes there-after. 
Sero-negativity increases to 42% after 19-24 months. 
7.3.1.5. Late latent syphilis (table7.6; figs. 7.1 through7.5): 
.!.<2.1 !!'~ 
The median is at titre 1:1 before treatment, and 4-5 years later attains 
the borderline between negative and dubious. Sero-negativity is 48% be-
fore treatment and virtually unchanged (SO%) 4-5 years later . 
.YQ'3.l:. 
The median is at the borderline between negative and dubious before 
treatment, and remains there throughout the period of observation. Sero-
negativity is 57% before treatment and increases to 67% of the patients 
still available after 4-5 years. 
BE'£F:. 
The median is at titre 1:2 before treatment, remains virtually unchanged 
and is at titre 1:1 after 4-5 years. Sero-negativity is 18% before treat-
ment and likewise remains virtually unchanged throughout the period of 
observation . 
.EI6-.8§§. 
The median is within the range of 2+ reactivity before treatment as well 
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as after. Sero-negativity varies from 5% before treatment to 8% after 
3-4 years . 
.I.E!... 
The median remains within the positive range throughout the period of 
observation. Sero-negativity remains virtually unchanged. 
7. 3. 2. Comparison of patients with early infectious syphi 1 is treated with 
different penicillin dosages 
So far as the size of the groups after treatment and the number of obser-
vations per test permitted, the results of serological tests were compared 
in patients with sere-changing and sero-positive primary syphilis, sec-
ondary syphilis and early latent syphilis, who were treated with different 
penicillin dosages. The course of the Kolmer, VDRL, RPCF, FTA-ABS 
and TPI tests after treatment with at 1 east 31. 2 mi 11 ion I U pen ici 11 in over 
at least 6 weeks was compared with that after treatment with 10.8 million 
IU over 6 weeks. The relevant data are presented in tables 7. 7 through 
7. 14. 
For the majority of the gauge-dates within a period of observation of up 
to 2 years after institution of treatment, no significant differences were 
demonstrable in the course of the serological tests after these two thera-
pies (Wilcoxon's two-sample test, two-sided). In this context it should be 
pointed out that this was a retrospective study of several groups of 
patients, without randomization of therapies given. A striking finding was 
the sometimes very marked increase of the median of some tests shortly 
after institution of treatment in the patients with sere-changing primary 
syphilis (VORL, therapy 31.2 million IU; RPCF, therapy 10.8 million IU). 
This increase proved to be significant only in the VORL (Wilcoxon's 
signed-rank test, right-sided). 
The course of the serological tests in patients with late latent syphilis 
after different therapies was not compared because hardly changes 
occurred in these tests after treatment (fig. 7. 1 ). 
7. 4. Discussion 
The extent to which the stage of syphilis influences the course of sero-
logical tests after treatment is apparent from the graphs and from the 
sero-negativity percentages after treatment, both for non-treponema! and 
for treponema! tests. Comparison with observations reported by other 
authors is possible only on the basis of sero-negativity. Table 7.15 
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summarizes the results obtained in a number of recent studies of the 
course of serological tests after treatment, expressed as (percentage of) 
sero-negativity. VVe found no publications presenting comparable graphic 
representations of the course of serological tests in well-defined groups 
of syphilis patients after penicillin treatment. 
For primary syphi I is, comparison of sero-negativity percentages as cal-
culated for our patients is possible only with findings reported by Fiumara 
(1977), who separately studied a group of patients with sero-positive (RPR 
and FTA-ABS) primary syphilis. The importance of this subdivision in the 
evaluation of results of serological tests after treatment is demonstrated, 
not only by the graphic representation of their course but also by the fact 
that the Kolmer and VDRL tests are negative at 6-7 months after treatment 
in all patients with sere-changing primary syphi I is. In sero-positive prim-
ary syphilis, however, this is not the case until after 18-24 months. The 
other tests. too, show unmistakable differences between these two sub-
groups of primary syphilis. 
Comparison of the results of posttherapeutic serological tests in second-
ary syphilis with the data from the literature in table 7.15 reveals good 
agreement in the Kolmer, VORL, RPCF and FTA-ABS tests. The non-
treponema! tests are negative in SO% of patients 6-9 months after treat-
ment, and in 90% after 3-4 years. At this time, 79% of patients still have 
a positive RPCF and 95% still a positive FTA-ABS test. In secondary 
syphilis, TPI sero-negativity increases to 70% after 3-4 years. Nielsen 
and Reyn (1956) collected the results of a large number of studies of the 
posttherapeutic course of TPI results, regardless of the interval between 
treatment and TPI testing. They calculated that the TPI was negative after 
penicillin treatment in 49.5% of patients with secondary syphilis. Only 
one of the studies referred to by Nielsen and Reyn (Edmondson eta!., 
1955) specified the interval after treatment. TPI sero-negativity in second-
ary syphilis was 76% 4 years after treatment, and the authors emphasize 
that in this group the number of TPI-negative patients distinctly increased 
between 1 year and 4 years after treatment. Our own findings indicate that 
it is not until a fairly long time after treatment that TPI tests become nega-
tive; calculation of sero-negativity percentages without taking into account 
the interval after treatment would therefore seem to make little sense. 
Remarkably few studies seem to have been devoted to the course of sero-
logical tests after treatment of patients with early latent syphilis. On the 
course of the TPI after treatment of early latent syphilis, the literatur-e stud-
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ied provided no data whatever. Personal observations revealedaslight de-
crease of the median from positive to dubious, with an increase of sero-
negativity to 42% after 19-24 months. Hates (1972) found a negative Kolmer 
or VORL test in 58.3% of patients with early latent syphilis 24 months 
after treatment. This is in good agreement with our findings: 56% Kolmer 
sero-negativity and 52% VORL sero-negativity 19-24 months after treat-
ment for early latent syphilis. No satisfactory explanation has been found 
for the increase of the Kolmer median after zt-3 years and after 3-4 
years, while the median of the other non-treponema! and treponema! tests 
remained unchanged. 
In late latent syphilis, treatment proves to exert virtually no influence on 
the results of non-treponema! and treponema! serological tests. This was 
established as early as 1935 for treatment with bismuth and salvarsan 
(League of Nations 1935), and confirmed also for penicillin treatment 
(ldsoe et al., 1972). 
The course of non-treponema! and treponema! tests after treatment with 
at least 31.2 million IU penicillin over at least 6 weeks proved not to 
differ significantly from that after 10.8 million IU penicillin over 6 weeks. 
Perdrup (1960) concluded from a comparative study that there were no 
clinical or serological differences after treatment of early syphilis with 
6 or with 12 million IU penicillin in daily doses of 600.000 IU procaine-
penicillin G in oil with 2% aluminium monostearate (PAM) over 10 or 20 
days. After treatment of secondary syphilis with 6 million IU penicillin 
given as 2.4 or 1.2 million IU benzathine penicillin G (Peniduraj!!} every 
3-5 days, Durst et al. (1973) found a more rapid return of the VORL to 
sero-negativity than after a single dose of 2. 4 or 4. 8 million IU of the 
same agent. Partly in view of the lastmentioned study, the New York City 
Department of Health and other agencies are now recommending more 
prolonged penicil fin courses with larger doses than those recommended 
by the Center for Disease Control, Atlanta (USA) and the WHO (Cave, 
1975) . 
The increase of the VDRL median shortly after institution of treatment 
in patients with sere-changing primary syphilis proved to be statistically 
significant. Other authors have also reported this (Hoekenga, 1949; 
Perdrup, 1960; Fiumara, 1964; Wiedmann, 1964; Grabner, 1969), but 
only Wiedmann (1964) suggested a possible explanation: he thought that 
these patients must have been treated exactly at the time the serological 
tests changed, which might explain why this increase in sere-reactivity 
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is not observed in other stages of syphilis. Another explanation might be 
that treponemata killed by the treatment release large amounts of antigens 
within a short time. 
Antibody production after an infection with T. pal I idum can be influenced 
by treatment aimed at elimination of the causative agent. As the infection 
has been of longer duration and therefore the antigenic stimulus has been 
present longer, antibody production can be more permanently influenced 
by the development of so-called infection immunity. This infection immuni-
ty has been demonstrated experimentally by inoculation ofT. pallidum in 
healthy test subjects as well as in treated and untreated syphilis patients 
(Magnuson et al., 1956). In persons with a history of infection with 
T. pallidum, even if treated in the primary stage 7 immunological behaviour 
after re-infection proved to differ from that of healthy test subjects. This 
was apparent in particular from an accelerated humoral response after re-
infection, demonstrable both in non-treponema! and in treponema! tests. 
Those previously treated for one of the forms of early syphilis, nearly 
always developed clinical signs of a new infection after re-infection, 
whereas patients with untreated latent syphilis did not. 
Investigations done by Fiumara (1977) revealed that, after treatment for 
re-infection of patients with a history of primary, secondary or early 
latent syphilis, it took much longer for the non-treponema! tests to show 
a distinct fall in titre than after treatment of a primary infection. 
The question arises whether persistent positivity of serological tests 
long after treatment in various (mostly later) stages of syphilis might be 
evidence of •truer immunity and the development of an immunological mem-
ory. In this respect the possibility should be taken into account that the 
residual titres corresponding with this immunity are maintained by contacts 
with non-treponema! pathogens, e. g. in the oral cavity. 
Some syphilis patients given what is believed to be adequate therapy show 
no significant decrease in non-treponema! antibodies (present in high 
titres prior to treatment) during a follow-up period of at least 2 years. 
This phenomenon is called sero-resistance. Several authors (Moore et 
al., 1938; Ourel et al. 7 1965; Wigfield, 1965; Ehrmann, 1967) believed 
that in these patients there might be persistence of the active infection, 
calling for re-treatment. In the context of this study, the data on the 14 
patients with sero-resistance have not been further analysed. In 9 of these 
14 patients, all given several courses of penicillin, Schuller (1973) found 
a high incidence of immunological anomalies consistent with auto-immune 
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diseases, and liver function disorders. Extensive neurological and inter-
nal examinations revealed nothing consistent with late symptomatic syphilis, 
nor were signs of activity of the original infection found. Analogous to 
similar anomalies described in the literature in patients with chronic bio-
logically false-positive tests, Schuller suggested that these sero-resistant 
patients could be suffering from an infection with T. pallidum, superimposed 
on pre-existent chronic biologically false-positive tests. 
Persistent positivity of specific treponema! tests in a number of treated 
syphilis patients, as observed also in this study, has prompted speculations 
in the literature about persistence ofT. pallidum in the organism after 
treatment considered to be adequate. Collart (1974) holds that it is not 
certain that all basic principles of penicillin treatment, e. g. the generation 
time ofT. pallidum, still apply in late stages of syphilis. Several authors 
(Yoder, 1975; Ritter, 1975; Mohr et at., 1976; Tramont, 1976) described 
failures with the conventional, internationally recommended doses of peni-
cillin in the treatment of patients with neurosyphilis. In some of these 
patients the presence ofT. pallidum was demonstrable after completion of 
treatment, and this prompted the advice to treat patients with neurosyphilis 
by intravenous injection of very large doses of penicillin. The possibility 
of persistence ofT. pallidum, even after treatment, was a reason for ad-
hering to fairly protracted penicillin treatment (as measured by interna-
tional standards) in all forms of syphilis seen at the dermato-venereolog-
i cal out-patient clinic of the Rotterdam University Hospital. 
Luger (1980) presented numerous arguments which cast doubt on the con-
clusions of studies describing persistence of treponemata after penicillin 
treatment. He maintained that treponemata might occasionally survive 
penicillin treatment, but that the clinical consequences of such survivals 
are of minor importance. Re-treatment should always be effective in such 
cases. 
7. 5. Conclusions 
A graphic representation of the course of various non-treponema! and 
treponema! serological tests over a period of 2-5 years after penicillin 
treatment of patients with various stages of syphilis shows that the stage 
of the disease at the time of treatment exerts a marked influence on the 
course of these serological tests. As the disease has existed longer, the 
decrease in reactivity of the various tests occurs later, or not at all. 
After treatment of early infectious syphilis, the course of non-treponema! 
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tests differs markedly from that of treponema! tests. The non-treponema! 
tests show a marked fall in titre (decrease in reactivity) after treatment 
in all stages of early infectious syphilis, even though there are differences 
between the individual stages. The treponema! tests, however, show a 
much less marked tendency to become negative after treatment. In second-
ary syphilis, TPI sero-negativity is 67% after 2i-3 years, and the FTA-
ABS in fact remains positive in the majority of patients tested 3-4 years 
after treatment. In early latent syphilis, the number of patients with a 
negative FTA-ABS does not increase after treatment. The TPI median 
shows hardly any decrease, but sero-negativity increases to 42% after 
19-24 months. In late latent syphilis, penicillin treatment is found not to 
influence the course of various serological tests over a follow-up period 
of 4-5 years. 
Exact classification of the disease prior to treatment, and taking into 
account the time of treatment, are of great importance in evaluating re-
sults of serological syphilis tests. Otherwise the serological results may 
be misinterpreted as indicating that treatment has been inadequate. 
Studies not specifying how long after treatment and in which stage of 
syphilis the observations were made, can therefore provide no reliable 
information on the course of a test after treatment. 
In non-randomized studies, no significant differences have been found be-
tween the course of serological tests after treatment with at least 31.2 
million IU penicillin over at least 6 weeks, and that after treatment with 
10.8 million IU over 6 weeks. 
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Table 7.1 
Total number of patients, subdivided according to treatment 
sero- sero~ secondary early late 
changing positive syphilis latent latent 
primary primary syphilis syphilis 
syphilis syphilis 
31.2 million lU pen. 17 3 8 7 4 
31.2 + 14.4 million IU pen. 8 3 5 3 4 
31.2 + 14.4 + 14.4 million IU pen. 4 10 18 20 19 
total at least 31.2 million IU pen. 29 16 31 30 27 
20.4 million IU pen. 30 10 13 7 12 
10.8 million IU pen. 42 17 38 27 18 
total treated with pen. 102 43 82 64 57 
60 g tetracycline* 2 0 7 2 12 
different therapy * 4 2 4 7 18 
no therapy* 9 3 5 45 
* The data on these patients were not further analysed in this study. 
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Table 7.2 
Number of patients (n), median (Me) of observations and sero-negativity(% sere-neg.) per test, arranged by gauge-date. 
Primary syphilis, sere-changing, Therapy penicillin (total group). 
Kolmer VDRL RPCF FTA-ABS TPI 
Gauge-date n Me sero- n Me sero- n Me sero- n Me sere- n Me sero-
%neg %neg %neg %neg %neg 
0 99 0.8 65 101 0.9 53 98 2.1 48 67 3.1 10 92 0.6 77 
8 21 d 38 0.9 39 1.5 38 3.2 22 3.1 32 0.8 
22 42 d 26 0.6 26 0.6 26 0,9 29 2.9 18 0.6 
43 - 90d 78 0.6 90 81 0.5 91 78 0.7 76 55 2.7 13 41 0.6 78 
4 5m 40 0.5 41 0.5 40 0.6 27 2.3 18 0,5 
6 - 7m 29 0.5 100 30 0.5 100 29 0.6 90 24 1.8 33 12 0.5 92 
8 - 9m 17 0.5 17 0.5 17 0.5 10 2.3 8 0.5 
10 12m 17 0.5 17 0.5 17 0,5 100 15 0,8 60 8 0,5 100 
13 - 18m 25 0.6 25 0.5 25 0.5 22 1.3 15 0.6 
19 - 24m 19 0.5 18 0.5 18 0,5 18 0.7 73 13 0.5 
2 - 2!-S yr 14 0.5 14 0.5 14 0.5 13 0.7 6 0.5 
2!-S- 3 yr 5 0.5 5 0.5 5 0.5 5 0.5 100 
00 
(f) Table 7.3 , 
Number of patients (n), median {Me) of observations and sero-negativity{% sero-neg.) per test, arranged by gauge-date. 
Primary syphilis, sero-positive. Therapy: penicillin (total group). 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date n Me sera- n Me sera- n Me sero- n Me sero- n Me sero-
%neg %neg %neg %neg %neg 
0 43 8.4 0 43 2.5 0 43 6.4 0 25 3.3 0 40 2.4 0 
8 21 d 17 6.6 17 2.5 17 6.2 5 2.8 8 2.2 
22 42d 18 4.0 18 2.4 18 5.5 12 3.3 6 1.0 
43 - 90d 27 3.9 30 28 2.3 28 27 4.5 18 19 3.4 5 12 1.0 50 
4 - 5m 24 0.7 24 0.8 24 4.0 11 3.4 10 2.0 
6 - 7m 23 0.6 83 23 0.6 87 23 2.2 43 14 3.4 7 11 0.8 63 
8 9m 15 0.6 15 0.6 15 0.8 8 3.3 6 0.7 
10 12m 11 0.8 11 0.6 11 0.9 11 3.2 6 1.0 
13 18m 21 0.6 21 0.6 21 0.8 17 2.6 13 0.8 
19 - 24m 15 0.5 100 15 0.5 100 15 0.8 60 13 2.3 15 11 0.6 82 
2 - 2~ yr 8 0.6 8 0.5 8 0.7 75 8 0.8 62 5 0.6 80 
Table 7.4 
Number of patients (n), median (Me) of observations and sero-negativity (%sera-neg.) per test, arranged by gauge-date. 
Secondary syphilis. Therapy: penicillin (total group). 
Kolmer VDRL RPCF FTA-ABS TPI 
Gauge-date n Me sero- n Me sero- n Me sera- n Me sera- n Me sera-
%neg %neg %neg %neg %neg 
0 81 10.4 0 82 2.5 0 81 8.4 0 49 3.1 0 71 2.5 0 
8 - 21 d 40 9.2 40 2.5 40 7.9 21 3.3 15 2.5 
22 42 d 30 7.3 30 2.5 30 6.9 25 3.1 12 2.5 
43 90d 79 6.3 6 79 2.4 11 79 5.9 8 49 3.0 0 29 2.5 3 
4 5m 58 3.5 58 2.1 58 4.4 32 3.1 25 2.3 
6 - 1m 51 1.0 51 51 1.1 49 50 3.8 16 31 3.3 0 22 2.4 
8 9m 29 0.7 29 0.6 29 2.9 22 3.1 17 2.2 
10 12m 28 0.6 89 28 0.5 93 28 2.7 19 2.7 10 19 2.0 32 
13 - 18m 57 0.5 58 0.5 57 2.5 30 45 3.1 42 2.1 
19 24m 32 0.6 92 32 0.6 91 32 3.5 30 3.3 3 28 2.1 32 
2 2%: yr 19 0.5 19 0.5 19 3.7 26 16 3.1 12 2.0 
2~- 3 yr 12 0.5 13 0.5 12 3.7 33 13 2.6 8 6 0.7 67 
3 - 4 yr 19 0.5 95 19 0.6 89 19 3.7 21 19 3.1 5 10 0.7 70 
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Table 7.6 
Number of patients (n), median (Me) of observations and sero-negativity (% sero-neg.) per test, arranged by gauge-date. 
Early latent syphilis. Therapy: penicillin (total group). 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date n Me sero- n Me sero- n Me sero- n Me sero- n Me sera-
%neg %neg %neg %neg %neg 
0 64 8.3 0 64 2.5 0 64 7.4 5 46 3.4 0 45 2.5 0 
8 21 d 27 7.5 28 2.5 27 7.1 19 3.1 9 2.5 0 
22 - 42d 25 5.7 25 2.4 25 6.4 17 3.5 6 2.4 0 
43 90 d 51 6.1 16 52 2.3 21 52 6.2 0 37 3.1 0 15 2.3 20 
4 5m 40 3.7 41 2.2 40 5.0 24 3.3 13 2.5 0 
6 7m 43 3.9 32 43 2.0 32 42 4.7 12 31 3.3 0 17 2.1 18 
8 9m 21 4.2 22 2.0 22 5.0 13 3.6 10 2.4 10 
10 12m 30 2.2 47 30 0.8 60 30 5.0 17 24 3.4 4 14 2.3 21 
13 - 18m 38 0.9 53 38 0.7 71 38 4.3 33 3.3 21 2.3 33 
19 - 24m 25 0.9 56 25 1.0 52 25 4.2 12 25 3.0 12 2.0 42 
2 2~ yr 19 0.9 53 19 0.9 58 19 4.5 19 2.6 8 2.5 
2%- 3 yr 6 3.0 6 0.6 6 4.0 6 2.8 
3 - 4 yr 9 4.1 33 10 0.8 60 10 3.3 10 10 3.0 0 
Table 7.6 
Number of patients (n), median (Me) of observations and sero-negativity (%sera-neg,) per test, arranged by gauge-date. 
Late latent syphilis. Therapy: penicillin (total group). 
Kolmer VORL RPCF FTA-A8S TPI 
---
Gauge-date n Me sera- n Me sera- n Me sera· n Me sera- n Me sera-
%neg %neg %neg %neg %neg 
0 50 2.3 48 53 0.9 57 50 3.7 18 37 3.2 5 29 2.4 14 
8 - 21 d 12 3.0 17 0.7 12 3.3 11 3.4 11 2.4 
22 - 42d 27 1.0 52 27 0.9 55 27 3.3 18 22 3.3 9 6 2.4 
43 - 90d 52 2.6 55 0.9 51 3.3 41 3.1 20 2.5 
4 - 5m 37 2.5 40 0.8 37 3.6 33 3.2 16 2.4 
6 7m 40 3.5 44 0.9 39 3.0 38 3.1 16 2.4 12 
8 - 9m 21 2.5 22 1.9 21 3.7 16 3.3 12 2.3 
10 12m 25 4.1 25 1.0 25 3.8 25 3.5 12 2.5 8 
13 - 18m 31 2.6 35 0.7 32 3.7 34 3.1 22 2.5 
19 - 24m 18 1.9 18 0.7 18 4.4 16 3.4 14 2.3 
2 - 2!6 yr 12 0.9 12 0.9 12 3.5 12 3.6 6 2.3 
2!6- 3 yr 11 0.9 11 0.9 11 3.7 10 3.0 7 2.4 14 
3 - 4 12 0.7 12 0.7 12 3.0 8 3.0 8 10 2.3 15 
4 - 5 6 1.0 50 6 0.7 67 6 2.5 17 6 3.7 
(]J 
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Table 7.7 
Number of patients (n) and median (Me) of observations per test, arranged by gauge·date. 
Primary syphilis, sera--changing. Therapy: at !east 31.2 million !U penicillin. 
Kolmer VDRL RPCF FTA-ABS TPI 
Gauge·date n Me n Me n Me n Me n Me 
0 28 0.9 29 1.0 27 3.3 14 2.8 28 0.7 
8- 21 d 17 0.7 18 1.3 17 3.3 8 2.7 14 0.9 
22- 42 d 11 0.5 11 0.5 11 0.8 5 2.8 10 0.6 
43- 90 d 25 0.5 25 0.5 25 0.8 16 2.3 25 0.6 
4- 5m 21 0.5 22 0.5 21 0.6 8 2.0 11 0.5 
6- 7m 11 0.5 12 0.5 11 0.6 7 1.2 
8- 9m 10 0.5 10 0.5 10 0.6 
10- 12m 6 0.6 6 0.5 6 0.5 5 1.5 
13- 18m 7 0.5 7 0.5 7 0.5 
19- 24m 14 0.5 13 0.5 13 0.5 13 0.7 8 0.5 
Table 7.8 
Number of patients (n) and median (Me) of observations per test, arranged by gauge-date. 
Primary syphilis, sero·changing. Therapy: 10.8 mil! ion IU penici!!in. 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge--date n Me n Me n Me n Me n Me 
0 41 0.7 42 1.0 41 0.8 42 3.2 36 0.7 
8- 21 d 8 1.0 8 1.0 8 4.0 8 3.3 7 0.9 
22- 42 d 13 0.7 13 0.7 13 0.8 13 3.1 7 0.5 
43- 90 d 37 0.6 37 0.6 37 0.6 37 2.9 15 0.7 
4- 5m 17 0.5 17 0.5 17 0.5 17 2.5 6 0.6 
6- 7m 16 0.5 16 0.5 16 0.5 16 2.3 10 0.6 
8- 9m 
10- 12m 8 0.6 8 0.5 8 0.5 8 0.7 5 0.5 
13- 18m 15 0.7 15 0.5 15 0.5 15 1.5 12 0.6 
19- 24m 5 0.5 5 0.5 5 0.5 5 0.6 5 0.5 
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Table 7.9 
Number of patients (n) and median {Me) of observations per test, arranged by gauge-date. 
Primary syphilis, sero-positive. Therapy: at least 31.2 million IU pencil lin. 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date n Me n Me n Me n Me n Me 
0 16 8.0 16 2.5 16 7.0 15 2.4 
8- 21 d 10 6.0 10 2.5 10 6.0 
22- 42d 9 3.7 9 2.1 9 5.9 
43- 90d 16 3.7 16 2.3 16 5.3 7 3.3 7 0.9 
4- 5m 10 0.7 10 0.7 10 4.1 6 3.3 9 2.1 
6- 7m 15 0.6 15 0.5 15 2.5 6 3.3 5 0.8 
8- 9m 9 0.6 9 0.6 9 2.2 
10- 12m 5 0.6 5 0.5 5 4.5 5 3.2 
13- 18m 10 0.6 10 0.6 10 0.7 6 2.0 
19- 24m 6 0.5 6 0.5 6 1.0 
Table 7.10 
Number of patients (n) and median {Me) of observations per test, arranged by gauge-date. 
Primary syphilis, sero-positive. Therapy: 10.8 million IU penicillin. 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date n Me n Me n Me n Me n Me 
0 17 8.5 17 2.5 17 6.2 17 3.4 15 2.3 
8- 21 d 
22- 42d 8 1.0 8 2.5 8 4.3 8 3.3 
43- 90 d 10 1.0 11 2.2 10 2.8 11 3.5 5 1.5 
4- 5m 5 0.8 5 2.2 5 0.8 5 3.5 
6- 7m 8 0.7 8 0.7 8 1.0 8 3.4 6 0.7 
8- 9m 5 0.6 5 0.6 5 0.6 4 3.5 
10- 12m 6 1.0 6 0.6 6 0.7 6 3.3 5 
13- 18m 11 0.6 11 0.6 11 0.9 11 3.1 10 0.7 
19- 24m 9 0.5 9 0.5 9 0.7 9 2.5 7 0.6 
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Table 7.11 
Number of patients (n) and median (Me) of observations per test, arranged by gauge-date. 
Secondary syphilis. Therapy: at least 31.2 million IU penicillin. 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date 
0 
8- 21 d 
22- 42d 
43- 90d 
4- 5 m 
6- 7m 
8- 9m 
10- 12m 
13- 18m 
19- 24m 
Table 7.12 
n Me 
31 10.2 
20 8.5 
9 
31 
20 
30 
16 
17 
25 
20 
8.1 
6.5 
2.8 
0.9 
0.7 
0.5 
0.6 
0.6 
n 
31 
20 
9 
31 
20 
30 
16 
17 
26 
20 
Me 
2.5 
2.5 
2.5 
2.4 
2.1 
1.2 
0.7 
0.5 
0.5 
0.5 
n 
31 
20 
9 
31 
20 
30 
16 
17 
25 
20 
Me 
8.1 
7.3 
7.4 
6.1 
4.4 
4.0 
3.0 
2.9 
3.1 
3.7 
n 
10 
7 
5 
17 
12 
15 
9 
8 
13 
18 
Me 
2.8 
2.7 
3.0 
2.7 
3.0 
3.1 
3.1 
2.6 
2.7 
3.0 
n 
26 
5 
19 
19 
11 
6 
13 
16 
16 
Number of patients {n) and median (Me) of observations per test, arranged by gauge-date. 
Secondary syphilis. Therapy: 10.8 million IU pen·1cil!in. 
Gauge-date 
0 
8- 21 d 
22- 42 d 
43- 90d 
4- 5m 
6- 7 m 
8- 9m 
10- 12m 
13- 18m 
19- 24m 
BB 
Kolmer 
n 
38 
13 
21 
30 
19 
16 
13 
11 
31 
12 
Me 
10.4 
9.7 
7.1 
6.0 
4.8 
1.0 
0.6 
0.6 
0.5 
0.7 
VORL 
n 
38 
13 
21 
30 
19 
16 
13 
11 
31 
12 
Me 
2.5 
2.5 
2.5 
2.3 
2.1 
0.9 
0.5 
0.6 
0.6 
0.6 
RPCF 
n 
38 
13 
21 
30 
19 
15 
13 
11 
31 
12 
Me 
8.5 
8.2 
6.6 
5.5 
4.4 
3.2 
2.8 
2.3 
1.8 
3.4 
FTA-ABS 
n 
37 
13 
21 
30 
19 
16 
13 
11 
31 
12 
Me 
3.1 
3.5 
3.2 
3.2 
3.2 
3.7 
3.2 
2.7 
3.3 
3.7 
n 
35 
10 
8 
8 
5 
10 
11 
6 
25 
12 
TPI 
Me 
2.5 
2.5 
2.5 
2.4 
2.4 
2.3 
2.1 
2.0 
2.0 
Me 
2.5 
2.4 
2.4 
2.3 
1.5 
2.4 
2.2 
2.0 
2.2 
2.1 
Table 7.13 
Number of patients (n) median (Mel of obseJVations per test, arranged by gauge-date. 
Early latent syphilis. Therapy: 31.2 million IU penicillin. 
Kolmer VORL RPCF FTA-ABS TPI 
Gauge-date 
0 
8- 21 d 
22- 42d 
43- 90d 
4- 5m 
6- 7m 
8- 9m 
10- 12m 
13- 18m 
19- 24m 
Table 7.14 
n 
30 
14 
12 
22 
Me 
8.2 
7.7 
5.8 
6.2 
29 4.1 
28 4.0 
16 3.0 
17 
18 
20 
0.9 
0.9 
0.9 
n 
30 
14 
12 
22 
30 
28 
17 
17 
18 
20 
Me 
2.5 
2.5 
2.5 
2.4 
2.3 
2.1 
2.1 
0.8 
0.6 
2.0 
n 
30 
14 
12 
22 
29 
27 
17 
Me 
7.8 
7.4 
7.0 
6.6 
5.4 
5.2 
4.8 
17 4.9 
18 4.4 
20 4.3 
n 
14 
7 
17 
13 
16 
8 
Me 
3.1 
2.9 
3.1 
3.3 
3.0 
3.3 
11 3.3 
13 2.9 
20 2.9 
n 
22 
8 
6 
9 
7 
8 
7 
9 
Number of patients {n) and median (Mel of obseJVations per test, arranged by gauge-date. 
Early latent syphilis. Therapy: 1 0.8 mill ion IU penicillin. 
Gauge-date 
0 
8- 21 d 
22- 42 d 
43- 90d 
4- 5 m 
6- 7 m 
8- 9m 
10- 12m 
13- 18m 
19- 24m 
Kolmer 
n 
27 
8 
Me 
8.6 
7.0 
13 5.5 
1S 
10 
15 
5 
12 
20 
5 
6.0 
2.0 
3.7 
5.3 
2.7 
1.0 
0.8 
VDRL 
n 
27 
8 
13 
18 
10 
15 
5 
12 
20 
5 
Me 
2.5 
2.3 
2.3 
2.3 
0.8 
1.5 
1.5 
1.0 
0.8 
0.6 
RPCF 
n 
27 
8 
13 
18 
10 
15 
5 
12 
20 
5 
Me 
7.2 
6.0 
6.2 
5.0 
4.0 
3.5 
5.5 
5.3 
4.2 
3.5 
FTA-ABS 
n 
27 
8 
13 
18 
10 
15 
5 
12 
20 
5 
Me 
3.5 
3.2 
3.6 
3.1 
3.0 
3.5 
4.3 
3.7 
3.5 
3.3 
n 
17 
5 
7 
6 
8 
6 
14 
TPI 
Me 
2.5 
2.4 
2.5 
2.4 
2.4 
2.3 
2.3 
2.1 
Me 
2.5 
2.5 
2.1 
2.4 
3.1 
2.3 
2.2 
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Table 7.15 
Results of studies of sero*negativity after treatment of various stages of early syphilis with penicillin 
(given in millions of International Units= mlU) 
diag* sero*negativitv (%) after months: 
no· 
therapy sis test 2 3 6 12 15 18 24 
FOrstrOm Proc.Pen.G: 
{1967) 7.2miU Sl Kolmer 43.0 70.0 96.7 
over 12 days VORL 58.0 90.0 100 
RPCF 74.0 90.0 93.4 
S II Kolmer 13.8 21.5 58.9 77.3 
VORL 17.3 21.5 82.4 81.9 
RPCF 48.3 57.2 53.0 36.4 
Smithurst Proc.Pen.G: 
11971 I 10*15 miU Sl Kolmer 96.0 
over 1 0-20 days VORL 96.0 
RPCF 84.0 
10-40 miU S II Kolmer 84.6 
over 1 0-40 days VORL 84.6 
RPCF 76.9 
Hat as Penidural 0/F: 
(1972) 6miU Sl Kolmer 55.6 69.6 84.2 90.8 
over 17 days or 
VORL 
Penidural D/F: S II Kolmer 0 47.7 62.5 76.9 76.3 84.2 
8.4 miU or 
over 24 days VORL 
SLR 4.5 22.5 31.4 41.9 50.0 58.3 
Gapinski Proc.Pen.G: Sl Kolmer 57.0 82.1 92.8 100 
(19721 4.2 or 6 miU 
Proc.Pen.G: S II Kolmer 20.0 52.0 60.0 84.0 
6.9 or 12 miU 
Penidural: Sl Kolmer 46.0 76.9 92.3 
2.4 or 4.8 miU 
over 1*12 days 
Penidural: S II Kolmer 31.5 63.1 84.2 100 
2.4 or 8.4 miU 
over 1-3 weeks 
Durst Penidural: 6 miU S II VORL 42.5 82.5 100 
(1973) over 6* 1 0 days 
Luger Long-acting Pen: Sl Kolmer 100 
(1974) over 14 days VORL 95.4 100 
FTA-ABS 42.1 69.2 68.7 80.0 
S II Kolmer 91.0 100 
VORL 9.0 27.3 83.3 83.3 
FTA-ABS 0 0 13.3 18.2 
Steinmann Long-acting Pen: Sl Kolmer 50.0 90.0 92.0 
(1976) over 2-4 weeks S II Kolmer 50.0 73.0 72.0 
Fiumara Penidural: 4.8 miU Sl RPR 32.6 47.4 79.4 100 
(1977) over 2 weeks S II RPR 34.5 67.0 84.0 96.1 100 
S I= primary syphilis; S II= secondary syphilis; SLR =early latent syphilis. 
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CHAPTER 8 
SCREENING TESTS. EFFECTIVENESS OF VARIOUS SEROLOGICAL 
TESTS OR TEST COMBINATIONS USED IN THE NETHERLANDS FOR 
DEMONSTRATION OR EXCLUSION OF INFECTION WITH TREPONEMA 
PALLIDUM IN VARIOUS POPULATIONS 
8. 1. Introduction 
Serological syphilis tests are performed in several different groups: 
1} patients suspected of having syphilis on the basis of history, clinical 
findings or epidemiological data; 
2} patients in whom another sexually transmitted disease has been demon-
strated, implying the risk of the presence of a simultaneously or not 
simultaneously acquired infection with T. pallidum as wei I; 
3} persons who have no complaints but present for examination with a view 
to the possible presence of a sexually transmitted disease; 
4) patients suffering from an internal, neurological, psychiatric or other 
condition, in whom syphilis is to be eliminated or in whom syphilis is 
suspected as a cause of the symptoms observed; 
5) blood donors; 
6) pregnant women. 
These groups differ, not only in the actual chance that an infection with 
T. pal I idum is present but also in terms of the consequences of missing 
the diagnosis of syphilis. 
An ideal serological syphilis screening test should have a high degree of 
sensitivity in alI stages of the disease. In addition, it should be sufficient-
ly specific, technically simple, quick, capable of being automated, and in-
expensive. 
A number of properties of various serological tests are schematical Jy 
summarized in table 8. 1. Since none of these tests seems to meet all the 
requirements, test combinations are often used. 
In the Netherlands, serological screening for syphilis is done mostly at 
district public health Jaboratorie·s, where several different tests are per-
formed. The guidelines provided by the National Institute of Public Health 
(Bilthoven} state that at least two tests should be performed at the district 
laboratories: a flocculation test in combination with either a non-trepo-
nema! complement fixation test or a treponema! test. Table 8. 2 presents 
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a survey of serological syphilis tests performed at 19 district public health 
laboratories (as per 31st August 1978). The VDRL/Kolmer combination 
was used for screening at 11, and the VDRL/RPCF combination at 2 labo-
ratories. At the request of the referring physician or in view of deviant 
findings at the first testing, several additiona-l tests might be performed, 
e. g. the Kolmer (quantitative) and/or RPCF and/or FTA-ABS and/or 
TPHA tests. 
This study attempts to establish whether with the VDRL/Kolmer and 
VDRL/RPCF combinations alI syphilis patients involved would have been 
identified. Since the TPHA test has recently been recommended also as 
a screening test (and is meanwhile being used at several laboratories), 
this test has been included in this study. 
8. 2. Material and methods 
The study encompasses the data on alI patients in whom 1syphil is 1 or 
1treated syphilis 1 had been diagnosed. In each part of the study, only 
the data on those cases in which all tests to be evaluated had been per-
formed could be considered. 
The patients in each diagnostic group were subdivided according to the 
results of the various serological tests. These were specifically the 
VDRL/RPCF combination followed by FTA-ABS and TPI, and the VORL/ 
Kolmer combination followed by FTA-ABS and RPCF. These data were so 
arranged as to indicate immediately the number of patients with various 
combinations of test results per diagnosis. In this context it should be 
borne in mind that the diagnoses were established, not exclusively on the 
basis of these serological data but on the basis of the criteria defined in 
Chapte.r 5 (section 5. 1 ). 
Table 8. 3 presents data on the sensitivity of the Kolmer, VDRL, RPCF, 
FTA-ABS, TPI and RPR tests as established in personal observations 
described in Chapter 6. Since these observations concerned a selected 
group of patients (i.e. syphilitic patients among those attending an out-
patient clinic for venereal diseases), they did not warrant any conclusion 
concerning the specificity of these tests. The data on the specificity of 
the Kolmer, VORL, RPCF and FTA-ABS therefore originate from a study 
made by sanffer et al. (1975) among patients attending the dermato-
venereological out-patient clinic of the Rotterdam University Hospital. 
The serological tests were all performed at the bacteriological laboratory 
of the Rotterdam Municipal Health Service, using the same techniques as 
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the National Institute of Public Health in Bilthoven. These data are listed 
in table 8. 4, along with data on RPR and TPHA results obtained in a 
prospective study carried out in collaboration with the National Institute 
of Public Health in Silthoven (Menke and Notowicz, 1980). The specificity 
of the TPI was set at 100%. 
The data on the cases of primary and secondary syphilis officially report-
ed in 1979 were supplied by Dr H. Bijkerk (Division of Infectious Diseases, 
Office of the Chief Medical Officer of Public Health, the Netherlands). 
Other stages of syphilis are not notifiable in The Netherlands, nor are 
nation-wide data on these stages otherwise available. According to the 
American Center for Disease Control (Issue no. 128, Sexually Transmit-
ted Diseases, Statistical Letter, 1980), the ratio between officially re-
ported cases of primary plus secondary syphilis, early latent syphilis, 
and late latent plus late syphilis per 100,000 USA population was 10:9.1: 
10.6 in 1978. This means that the total number of officially reported cases 
of syphilis in the USA is three times the number of cases of primary and 
secondary syphilis. In The Netherlands, the number of reported cases of 
primary and secondary syphilis was 8.5 per 100,000 population in 1979. 
Analogous to the situation in the USA, the incidence of all stages of 
syphilis in The Netherlands was likewise presumed to be three times the 
number of officially reported cases of primary and secondary syphilis. 
In 1979 the incidence of primary and secondary syphilis among patients 
attending the out-patient clinic for venereal diseases of the Rotterdam 
University Hospital Dijkzigt was 1.8%, versus an incidence of 3.4% for 
all stages of syphilis taken together. 
The data on the incidence of primary and secondary syphilis among blood 
donors were supplied by F. C. H. A. Kothe, director of the Rotterdam Blood 
Transfusion Service. 
The usefulness of a serological test is determined, not only by its specifi-
city and sensitivity but also by the predictive value of its positive or 
negative result. This predictive value depends, not only on the specifi-
city and sensitivity of the test but also on the incidence of the disease in 
the population tested (Vecchio, 1966). 
To calculate the predictive value of a positive and of a negative result 
of a serological syphilis screening test, the following equations were 
used: 
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PVpos 
PV 
neg 
number of syphilitics with a positive test 
total number of persons {syphilitics as well 
as non-syphilitics) with a positive test 
X 100 
number of non-syphilitics with a negative test 
total number of persons with a negative test X 100 
This means that the predictive value of a positive test result is the per-
centage of times that a positive test will detect a patient suffering from 
syphilis, while the predictive value of a negative test result is the per-
centage of times that a negative test will detect a non-diseased person 
(Vecchio, 1966). 
To calculate the probability that a patient is suffering from syphilis 
despite a negative test result (i.e. a false-negative test), the following 
equation was used: 
number of syph;l;t;cs (S+) w;th a negaUve test (T-) 
p (S + IT-) = X 1 00 
total number of persons with a negative test 
8. 3. Results 
Tables 8. 5 and 8. 6 list the diagnoses corresponding with each combination 
of serological test results. These data were used for further classifica-
tion. 
8. 3. 1. Patients with a negative VDRL/RPCF combination 
Proceeding from the numbers per diagnosis given in table 8. S, table 8. 7 
indicates the percentage of the total number of patients in this group and 
the percentage of the total number of patients with this diagnosis involved 
in the study. Of the patients with primary syphilis, 18% showed a nega-
tive VDRL/RPCF combination. The FTA-ABS was dubious or positive 
in all these patients. Of the total number of patients with untreated forms 
of syphilis, 20% showed a negative VDRL/RPCF combination. 
8. 3. 2. Patients with a negative VDRL/Kolmer combination 
Proceeding from the numbers per diagnosis given in table 8. 6, table 8. 8 
indicates the percentage of the total number of patients in this group and 
the percentage of the total number of patients with this diagnosis involved 
in the study. Of the patients with primary syphilis, 29% showed a nega-
tive VDRL/Kolmer combination. Of the total number of patients with un-
treated forms of syphilis, 37% showed a negative VDRL/Kolmer combi-
nation. 
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The FTA-ABS was dubious or positive in 89% of the patients with 
primary syphilis, and the RPCF was positive in 30%. 
8. 3. 3. Patients with a negative VDRL/FTA-ABS combination 
Proceeding from table 8. 5, table 8. 9 presents the distribution of patients 
with a negative VORL/FTA-ABS combination by diagnosis. It is apparent 
that the diagnosis would be missed on the basis of a single serological 
testing in 4% of patients with untreated forms of syphilis. 
8. 3. 4. Predictive values of the Kolmer VORL RPR RPCF FTA-ABS, 
TPI and TPHA tests 
The predictive values of positive tests (table 8. 1 0) are widely diverse 
for different tests and for different disease incidences. 
Given a low disease incidence, the predictive values of positive tests 
are more markedly influenced by minor differences in specificity between 
different tests (e. g. between Kolmer and VORL) (table 8. 4) than wh~n the 
disease incidence is higher. The predictive values of a positive Kolmer 
and VORL always substantially exceed those of the TPHA and FTA-ABS. 
Given a specificity of 100% (RPR and TPI), the predictive value of a 
positive test result is always 100%, regardless of the disease incidence. 
The predictive value of a negative test result has been calculated only for 
the group of blood donors, and is about 99. 9% for all the tests examined 
(table 8. 11). 
8.3.5. Probability of syphilis in the case of a negative test result 
Table 8. 12 lists for various populations the probability of syphilis in the 
case of a negative result of various tests. This probability of disease is 
lowest in the case of a negative TPHA, with FT A-ABS and RPR ranking 
next. It is highest in the case of a negative TPI, Kolmer and VORL. 
These differences occur both at a low and at a relatively high disease 
incidence. 
8. 4. Discussion 
The choice in favour of the VDRL/Kolmer and VDRL/RPCF combinations 
discussed here, was made in The Netherlands during the period 1955-
1960 on the basis of the tests then available. In The Netherlands, Bekker 
in particular investigated the value of these tests (Bekker and DeBruyn, 
1953; Bekker, 1960). In Great Britain (Sequeira, 1959} and the USA 
(Carpenter et al., 1960), too, testing schemes were at that time proposed 
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in which the VORL~ alone or in combination with the RPCF~ was considered 
sufficient for screening purposes. 
The groups 1, 2 and 3 mentioned in the introduction, correspond with the 
out-patient clinic population that provided the patients for this study. It 
was established that, using the VDRL/RPCF combination in a single 
testing, syphilis would not have been diagnosed in 20% of the patients 
with untreated forms of syphi I is. With the VDRL/Kolmer combination this 
would have been the case in 37% of the patients. With the VDRL/FTA-
ABS combination the diagnosis would have been missed much less often 
(in 4% of patients). 
In view of these findings it seems justifiable to doubt the effectiveness of 
the VDRL/Ko!mer and VDRL/RPCF combinations for serological testing 
of the persons in the groups 1, 2 and 3 mentioned in the introduction. 
Although the diagnosis 'untreated syphilis! would be missed far less 
often with the VDRL/FTA-ABS combination, this combination cannot be 
regarded as suitable for screening. This rejection is based on the elabo-
rateness of the fluorescence technique and the already mentioned (sub-
section 3. 3. 2. 2) occurrence of not readily interpretable fluorescence 
patterns and sometimes transient weakly positive tests. 
The patients of group 4, in whom a form of late symptomatic syphilis is 
to be excluded, play only a very minor role in this material. Both the 
VORL and the Kolmer test were negative in 54% of the patients with 
asymptomatic and in 12% of those with symptomatic neurosyphilis. This 
indicates that these tests are insufficient when some form of late symp-
tomatic syphilis is suspected. 
In a study of the rheumatoid factor in which the question of the test best 
suited for its identification was raised, Valkenburg (1974) tried to dis-
tinguish between the clinical and the epidemiological criteria to be ful-
filled by such a test. An analogous distinction might be made with regard 
to serological syphilis tests. The clinician regards the results of sero-
logical testing as an aid in establishing the diagnosis, and therefore de-
mands a high sensitivity, but also the highest possible rate of negative 
test results in non-diseased persons. On the other hand, however, the 
risk of a negative test result in a syphilitic person should be minimal. 
From the epidemiological point of view, the screening of large population 
groups expected to include only a small number of patients is primarily 
intended to trace as many diseased persons as possible, and not to over-
look too many. The number of false-positive results of the tests used 
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should not be too large. These points of view differ only in the degree 
of importance attached to sensitivity and specificity. 
Our personal observations were made in a selected group of patients (in 
whom syphilis 1 treated or untreated, had been diagnosed). Our results 
can therefore not be simply extrapolated to serological studies of the 
presence ofT. pallidum infections in other groups, and particularly in 
groups in which the expected number of syphilis patients is much smaller. 
Applying Bayes rule, an a priori probability, e.g. the incidence of 
syphilis 1 can with the aid of laboratory data {specificity and sensitivity 
of a test) be adapted to the result of that test and turned into an a poste-
riori probability of disease for a given test result. The thus established 
predictive value of a test result can then be used in decisions about 
screening programmes. In addition, the possible occurrence of false-
negative tests is also of importance, dependent on the diagnostic situation. 
Table 8. 10 demonstrates the extent to which the predictive value of a 
positive test is dependent on the syphilis incidence. In a population with 
a low syphilis incidence, the predictive values of positive test results 
are likewise very low. Inter-test differences are marked in that case. 
The predictive value of a positive test result increases as the syphilis 
incidence increases. Given a relatively high disease incidence, as among 
patients attending the out-patient clinic for venereal diseases of the 
Rotterdam University Hospital, the predictive value of positive non-trepo-
nema! tests is likewise very high. 
Even with a low disease incidence, the predictive values of positive 
Kolmer and VDRL tests are the highest, which is to say that the proba-
bility of syphilis is highest when these tests are positive. 
This might be an important argument in favour of the use of one or several 
of these tests in epidemiological studies of populations with a low syphilis 
incidence. But this does not apply to studies of populations with a low 
syphilis incidence in which a missed diagnosis of syphilis might have 
serious consequences 1 as for example in blood donors. Among blood 
donors, the predictive value of a negative result is about 99.9% for all 
tests; this is to say that a blood donor with a negative test is almost cer-
tainly not suffering from syphilis. Another important point in blood donors 
is the probability of syphilis in spite of a negative test result. 
Table 8.12 shows that this probability is lowest for the TPHA, with FTA-
ABS and RPR ranking next. ln view of data on Rotterdam blood donors 
{1978), the Kolmer can be expected to be false-negative in 3. 6, and the 
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TPHA in 0. 5 per 100,000 donors. The data on the specificity of the 
various tests (table 8.4) can be used also to calculate the number of false-
positive tests to be expected. This number is 100 per 100, 000 persons 
with the Kolmer, and 1500 per 100, 000 with the TPhA test. 
For the group of blood donors, the fact that the probability of a false-
negative test is seven times as high with the Kolmer as with the TPHA 
must be weighed against the fact that the probability of a false-positive 
test is fifteen times as high with the TPHA as with the Kolmer. In view 
of the possible consequences of a false-negative test result in blood donors, 
it can be concluded that the TPHA is to be preferred as a screening test 
for blood donors. 
In the serological testing of the other groups mentioned in the introduction, 
it is up to the clinician to decide whether the sensitivity of a test in various 
stages of syphilis and the predictive value of a test should not be regarded 
as very important in these groups as well. If so, then he needs a combina-
tion of a test with a high predictive value of a positive result with a test 
that carries a minimal risk of a false-negative result. As stated earlier, 
non-treponema! tests have the highest predictive value of positive results. 
The high sensitivity of the RPR, especially in primary syphilis was shown 
in Chapter 6. In addition it has a high specificity, which combined with the 
high sensitivity of the TPHA in all other stages of the disease lead to the 
conclusion that the RPR/TPHA combination is the combination of choice. 
Numerous authors have in recent years recommended the use of the TPHA 
in combination with VORL or RPR (QtNeill eta!., 1973; Young et al., 
1974; Luger and Spend! ingwimmer, 1974; Kerf et al., 1976; Ehrke et a!., 
1977; Hagedorn and Naumann, 1979). Verlaeckt et al. (1976) advocated the 
use of the RPR in combination with both TPHA and FTA-ABS. This ad-
vice is based in particular on the possibility which this triple combination 
affords to trace both false-negative and false-positive results of these 
two treponema! tests at the very first testing. 
The high sensitivity of the RPR in early primary syphilis has already been 
discussed (section 6. 3. 1). In many patients with treated syphilis, the 
TPHA is still positive eyen after several years (Sequeira and Eldridge, 
1973). Although our personal experience in this respect is limited, data 
from the literature seem to indicate that quantitative performance of the 
TPHA makes little sense. The graphs indicating the course of serological 
syphilis tests befor:-e and after treatment (Chapter 6 and 7} show that non-
treponema! tests, if quantitatively performed, are most suitable as aids 
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in establishing the correct diagnosis (or in determining the stage of disease). 
In addition, they can be used in the follow-up after completion of therapy. 
An important advantage of the use of the RPR/TPHA combination at all 
district public health laboratories in The Netherlands lies in uniformity, 
which ensures that referring physicians are no longer confused by a large 
number of different tests used at different laboratories. 
8. 5. Conclusions 
In view of the results of this study it is evident that the VDRL/Kolmer and 
VDRL/RPCF combinations widely used in The Netherlands are unsuitable 
for serological testing of patients suspected of syphilis in view of medical 
history, clinical s.Jrmptoms or epidemiological data or in whom syphilis is 
a possibility or a fear. Moreover, these tests are inadequate also for 
definite exclusion of syphilis in patients with internal, neurological, 
psychiatric or other affections. 
In determining a choice from various serological syphilis tests for screen-
ing purposes, the predictive value of these tests as such is a factor of 
only I imited importance. Only in large-scale epidemiological screening of 
populations with a low syphilis prevalence, without clinical consequences, 
will the predictive value mainly play a role in the choice of tests to be 
used. 
In view of the possible consequences of a missed diagnosis of syphilis in 
blood donors, serological screening of this particular group should be 
done with a test that carries a minimal risk of a false-negative result. 
The TPHA meets this requirement, and also other requirements to be 
made in this context, e. g. possibility of automation and quickness of proce-
dure. 
In the other target groups of serological screening mentioned in the intro-
duction, it is in particular a high predictive value of a positive result in 
combination with high individual sensitivity in various syphi I is stages that 
plays an important role in the choice of the tests to be used. The RPR/ 
TPHA combination meets all reasonable requirements. 
An important advantage of the use of the recommended tests at all district 
public health laboratories would be uniformity, which has long been lacking 
at this level. 
Since the TPHA remains positive for a long time in patients with treated 
syphilis, particularly in later stages, and often shows no or little inclina-
tion to decrease in titre, there should be facilities for performing the non-
102 
treponema! test in question (in this case the RPR) quantitatively at the 
request of the referring physician. Outside the scope of this discussion of 
screening tests, mention must be made of the necessity, in the case of a 
positive test result, of facilities for quantitative performance of the non-
treponema I screening test in question for the purpose of further staging 
of the patient's disease process. For purposes of verification, it should 
remain possible in The Netherlands to have other treponema! tests (in 
particular the FTA-ABS and preferably also the TPI) performed. 
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0 Table 8,1 
... Survey of a number of properties of various serological syphilis tests 
Kolmer VDRL RPR RPCF TPI FTA·ABS TPHA 
Type of test Complement Flocculation Flocculation Complement lmmobili- Immune- Haemagglutination 
fixation fixation zation fluorescence 
Type of antigen non· non- non- group-specific type-specific type-specific type-specific 
treponema! treponema! treponema! treponema! treponema! treponema! treponema! 
False-positive possible possible possible possible very rare possible possible 
tests 
Elaborateness marked slight very slight marked very marked moderate slight 
Duration 2 days 15 min. 10 min. 2 days 2 days ± 4 hours 1-4hours 
Automation possible possible possible possible impossible partly possible possible 
Sensitivity 
primary syphilis moderate high very high moderate low very high moderate 
other early syphilis very high very high very high very high very high very high very high 
late syphilis slight slight slight moderate very high very high very high 
treated early nil nil nil low moderate high very high 
syphilis 
treated late low low low moderate very high very high very high 
syphilis 
Table 8.2 
Survey of serological syphilis tests performed at 19 district public health laboratories. 
(as per 31st August 1978) 
Tests minimally 
performed 
Tests performed on indication (deviant findings at first testing or clinical 
findings) 
VORL + Kolmer Kolmer {quantitative) RPCF FTA-ABS TPHA 
11 9 7 1 
VORL + RPCF 
3 3 2 
VORL + TPHA 
2 2 
TPHA 
VORL 
2 2 2 
Table8.3 
SensitivitY of the Kolmer, VORL, RPR, RPCF, FTA-ABS, TPI and TPHA tests in various stages of 
syphilis. 
Kolmera VORL a RPRa RPCFa FTA-ABSa TPla 
Primary and secondary 70.9% 76.7% 91.5% 78.8% 
syphilis {untreated) 
All stages of 71.1% 71.6% 89.4% 82.9% 
syphilis (untreated) 
a Figures calculated on the basis of data presented in table 6.3. 
b Data taken from Menke and Notowicz (1980). 
Table 8.4 
95.3% 64.5% 
96.2% 75.6% 
SpecificitY of the Kolmer, VORL, RPR, RPCF, FTA-ABS, TPI and TPHA tests. 
99.9% 99.8% 100% 
a Data taken from sanffer et al. (1975) 
b Data taken from Menke and Notowicz {1980) 
c Presumed specificity 
97.6% 96.5% 100% 
TPHAb 
96.3% 
98.2% 
98.5% 
105 
0 Table 8.5 
"' Combinations of test results (VDRL/RPCF followed by FTA·ABS and TPI) 
VORL neg. VORL pas. 
RPCF neg. RPCF pos. RPCF neg. RPCF QOS. 
FTA Neg FTA± FtA Pos FTA Neg FTA± FTA Pos FTA Neg FTA± FTA Pos FTA Neg FTA± FTA Pas 
TPI TPI TPI TPI TPI TPI TPI TPI TPI TPI TPI TPI 
Diagnosis Neg Pas Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pos Neg Pas Neg Pas Neg Pos Neg Pos Neg Pas To!: 
Prim. syph. - 2 13 - 2 - 1 - 3 1 1 - - - 5 6 - 1 15 33 83 
Sec. syph. - - - - - - - - - - - - - - - - - - 1 49 50 
Early lat. syph. - - - - - - - - - - - - - 1 1 - - 1 29 32 
Late lat. syph. 1 - 2 - 1 - - - - - 9 - - - - - - - - - 4 17 
Card. vase. syph. 
Sympt. neurosyph. - - -
=I - - ~I - - =I - - - 3 6 Asympt. neurosyph. - - 1 - 2 - - - - 6 
Early cong. syph. 
Late cong. syph. - - - - - 1 - - - 1 2 
Treated prim. syph. 2 3 - 11 4 1 11 2 - - - 1 - - 1 36 
Treated sec. syph. - - - - 4 - - - - - - - 4 
Treated early lat. syph. - - - 1 1 2 3 - - - - - 2 9 
Treated late lat. syph. - - - 2 - - - 4 6 
Treated card. vase. syph. 
Treated sympt. neurosyph. - 1 1 I - - -1 - - -1 - - 2 4 
Treated asympt. neurosyph. 
Treated early cong. syph. 
Treated late cong. syph. - 1 - - - - - - 1 - - 3 5 
Treated other syph. - - - - - - 1 - - - - 1 2 
Syph.- unclass. 2 - 4 3 10 2 - 1 6 26 - 1 2 - - - 1 1 34 93 
Late lat. syph. or end trep. 2 - - 6 - - 1 1 13 - - - 1 - 9 33 
Total 7 9 3 28 19 9 1 2 2 30 63 1 1 7 9 2 3 18 175 389 
Table 8.6 
Combinations of test results (VDRL/Kolmer followed by FTA-ABS and RPCF) 
VORL neg, ______ VORL pas. 
___ Kolmer f\!eg -~- _Kolmer Pas ______ j~Qlm!!E Neg Kolmer Pas 
FTA--Neg FTA ±--FTA Po$ FTA Neg FTA ± FTA Pas FTA Neg FTA ± FTA Pas FTA Neg FTA ± FTA Pas 
RPCF RPCF RPCF RPCF RPCF RPCF RPCF RPCF RPCF RPCF RPCF RPCF 
Di~~nosis Neg Pas Neg Pas Neg Pas Neg Pas Neg Pas Neg Pos Neg Pas _N~~ Pas Ne_~ Pos Neg Pas Neg Pas _Neg Pas Tot. 
Prim. syph. 1 2 3 1 15 5 - 1 - 5 9 1 - 7 42 92 
Sec. svph. - - - - - - - - - - 54 54 
Early lat. syph, - - - - - - - - - 3 44 47 
Late lat. syph. 1 1 1 1 9 - 1 5 - 1 - 1 11 32 
Card. vase. syph, 
Sympt. neurosyph. - - - 11 - 21 - -~ - 5 8 
Asympth. neurosyph, 1 - 1 5 - 3 - - - - 3 13 
Early cong. syph, 
Late con g. svph. - - 1 - - - - - - - 1 2 
Treatedprim.syph. 2 6 3 1 12 14 - - - - - 1 - - 1 40 
Treated sec. syph. - 3 - 1 - - - - - - 4 
Treated early lat. syph, - - 1 5 1 1 - - - 2 10 
Treated late lat.syph. - - - - 3 - - 1 5 9 
Treated card. vase. syph, 
Treated sympt. neurosyph. - - - 2 I - -! - -1 - 4 6 
Treated asympt, neurosph. 
Treated early cong. syph, 
Treated late cong. sYPh. 1 - - - 1 - - - 1 - 3 6 
Treated other syph. - - - 2 - - - 1 - - 1 4 
Syph.-unclass. 6 4 4 2 12 32 1 1 17 - - 3 1 4 48 135 
Latelat.syph.orendtrep, 2 - 1 1 6 15 - - - 1 9 - - - 1 1 - - 1 1 19 58 
_ Total 12 13 13 6 50 92 1 1 1 2 42 1 1 6 15 2 1 2 17 243 521 
0 
" 
Table 8.7 
Distribution by diagnosis of patients with a negative VDRL/RPCF combination (on the basis of data 
in table 8.5) 
diagnosis number %of patients %of total number of 
with negative number of patients with 
VDRLIRPCF patients with FTA-ABS ± 
(n•66) this diagnosis or pos. 
primary syphilis 15 23% 18% (n=83) 15 
late latent syphilis 4 6% 22% (n=18) 3 
late latent syphilis or latent 8 12% 25% (n=32) 6 
endemic treponematosis 
unctassifiabte syphilis 19 29% 20% (n=93l 17 
untreated syphilis total 46 70% 20% (n=226) 41 
treated prim. syphilis 16 24% 29% 14 
treated other forms of syphilis 4 6% 13% (n=31) 4 
Table 8.8 
Distribution by diagnosis of patients with a negative VDR L/Kotmer combination (on the basis of 
data in table 8.6) 
diagnosis number % of patients %of total number of number of 
with negative number of patients with patients with 
VDRL/Kolmer patients with FTA-ABS± RPCF pas. 
(n•186) this diagnosis or pos. 
primary syphilis 27 15% 29% (n=92) 24 8 
tate latent syphilis 13 7% 41% (n=32) 12 10 
tate latent syphilis 25 13% 43% (n=59) 23 16 
or latent endemic 
trepqnematosis 
asympt. neurosyph. 7 4% 54% (n=13) 6 6 
sympt. neurosyph. 1Z'/o (n=8) 1 
late cong. syph. 1 50% (n=2l 1 
unclass. syph. 48 26% 39% (n=122) 38 38 
untreated syph. total 122 66% 37% (n•328) 105 111 
treated prim. syph. 38 20% 97% (n=39) 30 21 
treated other forms 15 8% 36% (n::o41) 14 10 
of syphilis 
Table 8.9 
Distribution by diagnosis of patients with a negative VDR L/'FTA-ABS combination (on the basis of 
data in table 8.5) 
diagnosis number % of total number of 
patients with this 
diagnosis 
primary syphilis 2 2% (n=83) 
tate latent syphilis 5.5% (n=18) 
tate latent syphilis or· latent 2 6% (n•32) 
endemic treponematosis 
unclassifiabte syphilis 4 4% (n•93) 
asymptomatic neurosyphilis 1 17% (n=6) 
untreated syphilis, total 10 4% (n•232) 
treated-primary syphilis 7 13% (n=55) 
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Table 8.10 
Incidence of syphilis and predictive values of positive Kolmer, VORL, RPCF, FTA~ABS and TPHA 
results a) 
Population Incidence Predictive values (in%) 
(in%) Kolmer VORL RPCF FTA-ABS TPHA 
Netherlands, 1979: 
primary and secondary syphilisbl 0.0085 5.70 2.95 0.30 0.23 0.55 
syphilis, all stages c) 0.0255 15.31 8.91 0.83 0.70 1.64 
Amsterdam, 1979: 
primary and secondary syphilis b) 0.098 41.02 27.33 3.12 2.60 6.03 
Rotterdam, 1979: 
primary and secondary syphilisb) 0.0303 17.69 10.41 0.98 0.82 1.95 
Utrecht, 1979: 
primary and secondary syphilis b) 0.019 11.87 6.79 0.62 0.51 1.22 
The Hague, 1979: 
primary and secondary syphilis b) 0.0098 6.50 3.62 0.32 0.26 0.63 
Rotterdam University Hospital Out~ 
patient Clinic for Venereal Diseases, 
1979: 
primary and secondary syphilis d) 1.8 92.85 87.54 37.56 33.29 54.55 
syphilis, all stages d) 3.4 96.15 93.10 53.61 48.94 69.74 
Rotterdam blood donors, 1978e) 0.0125 8.14 4.57 0.41 0.34 0.81 
a) Given a RPR and TPI specificity of 100%, the predictive value of positive RPR and TPI results is 
always 100%, regardless of the disease incidence. 
b) Data based on the number of officially reported cases of primary and secondary syphilis under 
the Infectious Diseases Control and Disease Cause Detection Act (1976). 
c) Incidence estimated on the basis of the ratio between primary/secondary syphilis and other stages 
of syphilis in the USA (1979). 
d) Data from out~patient clinic attendance records. 
e) Data supplied by F.C.H.A. Kothe, director of the Rotterdam Blood Transfusion Service. 
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Table 8.11 
Predictive values of negative Kolmer, VORL, RPR, RPCF, FT A·ABS, TPI and TPHA results in 
blood donors of the Rotterdam Blood Transfusion Service {1978). 
Prevalence of 
syphilis (in%) 
0.0125 
Table 8.12 
Predictive values {in %) 
Kolmer VORL RPR RPCF FTA-ABS TPI TPHA 
99.9964 99.9971 99.9993 99.998 99.9996 99.997 99.9997 
Probability (P (S+ I R-) that a patient is suffering from syphilis despite a negative test result in 
various populations (in %) 
Population Incidence Kolmer VDRL RPR RPCF FTA·ABS TPI TPHA 
prim./sec. 
syphilis 
(in%) 
Netherlands, 
1979 0.0085 0.0025 0.002 0.0007 0.002 0.0004 0.003 0.0003 
Dept. of derm. 
venerology, 
Rotterdam 
University 
Hospital, 
1979 1.80 0.53 0.43 0.15 0.40 0.09 0.64 0.07 
Rotterdam 
blood donors, 
1978 0.0125 0.0036 0.0029 0.001 0.0027 0.0006 0.0044 ~.0005 
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SUMMARY 
This thesis discusses the results of a study of various aspects of a number 
of serological syphilis tests. 
Chapter 1 out! ines the facts that prompted this study. Specifically, these 
were the problems encountered in actual practice in the interpretation of 
results of serological syphilis tests. These problems are due in part to 
inadequate knowledge, and partly also to the fact that a fair number of 
different tests are in use in The Netherlands. 
Chapter 2 presents a survey of clinical and therapeutic aspects of syphilis. 
Chapter 3 presents a survey of serological syphilis tests on the basis of 
data from the I iterature, proceeding from the division of these tests into 
non-treponema! and treponema! tests. This division is based on the origin 
of the antigen used in these tests. The various tests performed in The 
Netherlands receive special attention. In addition, the concepts of anti-
complementarity and biologically false-positive tests are discussed. 
Chapter 4 formulates the specific questions on which this study focuses: 
1) Which course do various non-treponema! and treponema! serological 
tests take when a venereally acquired infection with T. pall idum is left 
untreated, and when it is treated with penicillin, and are there differ-
ences after treatment according to two different treatment plans? 
2) Can two test combinations widely used in The Netherlands be regarded 
as effective in the detection of syphilis, and to which extent might the 
TPHA test contribute to this? 
Chapter 5 discusses the diagnostic criteria applied, serological tech-
niques, treatment, computer processing, statistical methods, mode of 
graphic representation, and the follow-up on treated patients. 
Chapter 6 describes the course of a number of non-treponema! and trepo-
nema! serological tests during an untreated infection with T. pallidum. 
The graphs indicating this are based on the median of the observations in 
the various groups before treatment. The percentage of positive tests 
(sere-reactivity) of the various tests in different disease stages is also 
calculated. In primary syphilis the VDRL sere-reactivity significantly 
exceeds that of the Kolmer test, and the following order of decreasing 
sensitivity is noted: 
FTA-ABS o.. RPR > RPCF ==- VDRL > Kolmer~ TPI. 
111 
The FTA-ABS and RPR are the most sensitive tests; the difference be-
tween these two tests is not significant. 
The order of decreasing sensitivity in late latent syphilis is: 
TPI ""FTA-ABS > RPCF"' RPR > VORL"" Kolmer. 
The graphs reveal marked differences in course between the various sero-
logical syphilis tests. In particular there is a distinct difference in course 
between the non-treponema! tests (Kolmer, VORL and RPR) and the type-
specific treponema! tests (FTA-ABS and TPI). 
Mention is made of the occurrence of high titres in non-treponema! tests 
in patients with symptomatic neurosyphilis. Arguments are marshalled to 
demonstrate the importance of repeated serological testing when syphilis 
is suspected. 
Chapter 7 presents graphs showing the course of the Kolmer, VDRL, 
RPCF, FTA-ABS and TPI tests over a period of 2-5 years after treat-
ment with penicillin. Mention is made of marked differences again found 
between non-treponema! and treponema! tests in patients with early in-
fectious syphilis. In late latent syphilis, penicillin treatment proves not 
to influence the course of the tests over a period of observation of 4-5 
years. As the disease has been of longer duration, the reactivity of the 
various tests diminishes later, or even not at all. An exact classification 
of the disease prior to treatment, and taking into account the time of treat-
ment, are of great importance in the evaluation of results of serological 
syphilis tests. In a non-randomized study, no significant differences were 
found between the course of serological syphilis tests after treatment 
with at least 31.2 million IU penicillin over at least 6 weeks, and that 
after treatment with 10.8 million IU penicillin over a 6-week period. 
Chapter 8 discusses the question whether a few test combinations widely 
used in The Netherlands -specifically the VDRL/RPCF and the VDRL/ 
Kolmer combination -are effective in demonstrating or excluding syphilis. 
In this context some important properties of the various serological tests 
are presented in tabulated form. The TPHA test, now in use also at sev-
eral laboratories, is included in this study. lt is demonstrated that, with 
the two test combinations mentioned, the diagnosis of syphilis would have 
been missed in 20.3% and 37.2%, respectively, of the syphilis patients 
considered in this study. Efforts are made to facilitate the choice of sero-
logical tests for screening purposes by calculating the predictive values 
of positive test results. Particularly in dealing with blood donors, it is 
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important also to know the risk that a donor is suffering from syphilis de-
spite a negative test result. It is concluded that this risk is smallest with 
the TPHA, and that consequently this test can be recommended for selection 
of blood donors. For serological syphilis testing of other groups, the use 
of the TPHA in combination with a non-treponema[ test, preferably the 
RPR, is recommended. Emphasis is placed on the important advantage of 
uniformity of the tests performed at various district public health labora-
tories; this can eliminate a possible source of confusion and misunder-
standing. 
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SAMENVATTING 
In dit proefschrift worden de resultaten besproken van een onderzoek naar 
verschillende aspecten van een aantal serologische syfilisreacties. 
In hoofdstuk 1 is aangegeven wat tot dit onderzoek aanleiding heeft gegeven. 
Met name zijn dit de in de praktijk gebleken problemen bij de interpretatie 
van resultaten van serologische syfilisreacties. 
Deze zijn deels te wijten aan gebrek aan kennis en anderdeels ook aan het 
vrij grote aantal verschillende reacties dat in Nederland verricht wordt. 
Hoofdstuk 2 geeft een overzicht van klinische en therapeutische aspecten 
van syfi I is. 
Hoofdstuk 3 geeft, op literatuurgegevens gebaseerd, een overzicht betref-
fende serologische syfilisreacties. Hierbij wordt uitgegaan van de ver-
deling van deze reacties in non-treponemale en treponemale reacties. 
Deze verde! ing is gebaseerd op de herkomst van het bij deze reacties toe-
gepaste antigeen. Vooral wordt ingegaan op de verschillende reacties die 
in Nederland verricht worden. Daarnaast worden ook nog de begrippen 
anti-complementariteit en biologisch vals-positieve reacties besproken. 
In hoofdstuk 4 worden de specifieke vraagstel I ingen voor het onderzoek 
geformuleerd: 
1) hoe is het beloop van een aantal non-treponemale en treponemale sero-
Jogische reacties, zowel bij het onbehandeld doormaken van een vene-
risch verworven infectie met T. pallidum als na een behandeling met 
penicilline, en zijn er daarbij nog verschillen na beharideling vel gens 
twee verschillende behandelingsschema's? 
2) kunnen een tweetal in Nederland vee! gebruikte combinaties van reacties 
als effectief bij de opsporing van syfilis worden beschouwd en in welke 
mate zou de TPHA hieraan kunnen bjjdragen? 
In hoofdstuk 5 worden achtereenvolgens de toegepaste diagnostische cri-
teria, serologische technieken, behandeling, computerbewerking, statis-
tische methoden, wijze van grafische weergave en nacontrole van behandel-
de pati en ten besproken. 
In hoofdstuk 6 wordt het beloop van een aantal non-treponemale en trepo-
nemale serologische reacties bij het zonder behandeling voortbestaan van 
een infectie met T. pallidum beschreven. De grafische weergave hiervan 
is gebaseerd op de mediaan van de waarnemingen bij de verschillende 
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groepen v66r behandeling. Tevens is het percentage positieve reacties 
(sero-reactiviteit) voor de verschillende reacties in verschillende ziekte-
stadia berekend. Bij primaire syfi!is blijkt dat de VORL significant vaker 
positief is dan de Kolmer en bestaat de volgende volgorde van afnemende 
gevoel igheid: 
FTA-ABS~RPR > RPCF~VORL > Kolmer-:::o.:TPI. 
FTA-ABS en RPR zijn het gevoeligst, het verschil in gevoeligheid tussen 
deze twee reacties was niet significant. 
Bij !aat latente syfilis is deze volgorde als volgt: 
TPI ""FTA-ABS > RPCF"" RPR > VDRL"' Kolmer. 
Uit de grafische weergave blijken grote verschillen in beloop van de diver-
se serologische syfilisreacties. Met name is het verschil duidelijk tussen 
het beloop van de non-treponemale reacties (Kolmer, VORL en RPR) en de 
type-specifieke treponemale reacties (FTA-ABS en TPI). Gewezen wordt 
op het v66rkomen van hoge titers in non-treponemale reacties bij patienten 
met symptomatische neurosyfilis. Er worden argumenten genoemd die het 
belang van herhaald verrichten van sero/ogisch bloedonderzoek bij ver-
denking op syfilis aangeven. 
In hoofdstuk 7 wordt een grafische weergave gegeven van het beloop van 
Kolmer, VORL, RPCF, FTA-ABS en TPI gedurende 2-5 jaar na behande-
ling met penicilline. Gewezen wordt op de grote verschillen die ook hierbij 
bestaan tussen non-treponemale en treponemale reacties bij patienten met 
vroege infectieuze syfilis. Bij laat latente syfilis blijkt dat behandeling 
met penicilline geen invloed heeft op het beloop van de reacties gedurende 
een observatieperiode van vier tot vijf jaar. Naarmate de ziekte Ianger 
heeft bestaan vindt afname van de reactiviteit van de verschillende reacties 
ook later, of zelfs in het geheel niet plaats. Een exacte classificatie van 
de ziekte v66r behandeling en het rekening houden met het tijdstip van be-
handeling zijn van groot belang bij het beoordelen van resultaten van sero-
logische syfilisreacties. Er blijken, bij niet-gerandomiseerd onderzoek, 
geen significante verschillen te bestaan tussen het beloop van serologische 
syfi!isreacties na behandeling met minstens 31,2 miljoen IE penicilline 
gedurende minstens 6 weken en 10,8 miljoen IE penicilline gedurende 6 
weken. 
In hoofdstuk 8 is nagegaan of enkele vee! in Nederland gebruikte combina-
ties van reacties, met name VDRL/RPCF en VDRL/Kolmer effectief zijn 
voor aantonen of uitsluiten van syfilis. In tabelvorm zijn hierbij nog enkele 
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belangrijke eigenschappen van de verschillende reacties genoemd. Tevens 
is de TPHA, die thans eveneens in een aantal laboratoria verricht wordt, 
bij het onderzoek betrokken. Het btijkt dat met het tweetaf bovengenoemde 
combinaties van reacties de diagnose syfilis bij 20,3% resp. 37,2% van de 
bij dit onderzoek betrokken syfilispatienten gemist zou zijn. Getracht wordt 
om het kiezen van, voor screening te verrichten, serofogische reacties te 
vergemakkelijken door het berekenen van de predictieve waarde van posi-
tieve test-resultaten. Daarnaast is vooraf bij bloeddonoren van belang te 
weten hoe groot de kans is dat een donor bij wie een negatieve reactie is 
gevonden, toch aan syfilis lijdt. Geconcludeerd wordt dat deze laatste 
kans het kleinst is bij de TPHA en dat daarom deze reactie voor keuring 
van bloeddonoren kan worden aanbevolen. Bij serologisch onderzoek voor 
het aantonen van syfilis bij andere groepen wordt gebruik van de TPHA in 
combinatie met een non-treponemale reactie, bij voorkeur de RPR geadvi-
seerd. 
Ook wordt gewezen op het belangrijke voordeel van een uniformiteit van 
door de streeklaboratoria te verrichten reacties, waardoor een mogelijke 
bron van verwarring en misverstanden kan verdwijnen. 
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